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Summary of the guidelines 
Objective 
The objective of this document is to provide guidance to the Institutional Research 
Ethics Committee (IREC) of the International Livestock Research Institute (ILRI) to help 
ensure quality and consistency in the ethical review of research conducted by or at ILRI. 
The document is brief, and where further guidance is required the IREC will be 
informed by the ‘Operational Guidelines for Ethics Committees that Review Biomedical 
Research’ (WHO, 2000). 
 
Role of IREC 
The IREC will review and consider for approval all ILRI research proposals with a view 
to safeguard the dignity, rights, safety and well-being of all actual and potential research 
participants and the wider community. The goals of research, however important, 
should never be permitted to override the health and well-being of the research 
subjects. 
 
The IREC will ensure that the cardinal principles of research ethics (autonomy, 
beneficence, non-maleficence and justice) are followed in planning, conduct and 
reporting of ILRI research. For this purpose, it will cover the aspects of informed 
consent; harms, risks and benefits; distribution of these; and provisions for appropriate 
compensations wherever required. It will review research proposals before the start of 
the study and develop procedures for monitoring the research throughout the study 
until, and after, completion. The committee will also examine compliance with all 
regulatory and donor requirements, applicable guidelines and laws, including national 
(local) laws. 
 
The mandate of the IREC will be to review all research projects to be conducted at ILRI 
or any other premises or field sites for which ILRI is responsible, and also to review any 
research projects which are led by ILRI scientists or have involvement of ILRI scientists 
as part of their duties as an ILRI employee. This is irrespective of the funding agency or 
the place of research and irrespective of the scope or nature of the research. Where 
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the research proposal is being led by another institute then ILRI approval will not be 
granted unless the proposal has been approved by the research ethics committee of the 
lead organization. The role of IREC can be modified according to the requirement of 
ILRI. 
 
Composition of IREC 
The IREC will be multidisciplinary and balanced with a mixture of people from outside 
and inside the institution; laboratory and non-laboratory scientists; and people with 
knowledge of bio-medical and non-biomedical fields.  
 
The composition will be as follows: 
• at least one third of the members male, and at least one third of the members 
female 
• the chairperson to have some training/experience in bioethics and leadership 
• one person without a health background 
• at least one member from outside the institute 
• at least one lay member 
• at least two members with research experience 
• at least one member with training/experience in human health 
• one member with knowledge/understanding of the Kenyan law 
 
The number of members shall be a maximum of 15 and 50% plus a lay person are 
required to compose a quorum. An additional person may be co-opted on the 
agreement of a majority of the IREC to provide specialist expertise. 
 
There shall be 5-9 ILRI IREC reviewers whose mandate will only involve reviewing ILRI 
IREC applications. They will not be attending IREC meetings and will not have the right 
to vote.   
 
Authority under which IREC is constituted  




• Appointment: Members will be appointed by the DG of ILRI  
• Duration of appointment: Members will serve for two years. They may resign 
or be replaced on two months’ notice from each side. The duration of the 
appointment is for a period of 2 years, and may be renewed. 
• Probation: New members will be appointed for one year at the end of this 
period their position will be reviewed by the ILRI DG and the Chair of the 
IREC and either continued for 2 years or discontinued. 
• Training: Members without an appropriate (determined by chair) and recent 
(last 3 years) training in ethics will be required to undergo a short training on 
research ethics (10-20 hours) considered appropriate by the IREC. The cost 
will be met by the IREC budget. 
• Confidentiality: all members should maintain absolute confidentiality of all 
discussions during the meeting and sign a confidentiality form. 
• Conflict of Interests: all members should declare conflict of interests. 
• Remuneration: Members from CGIAR centers will not receive any 
remuneration, per diem, honorarium or other payment for attending 
meetings and or for reviewing applications. If required by the Chair to travel 
for IREC purposes, normal ILRI travel policy and re-imbursements will apply. 




• The Chair will be an employee of ILRI; they will conduct all meetings of the 
IREC. If the Chair is not available, they will nominate an alternate Chair for 
the relevant time period.  
• The Secretary is responsible for overseeing the organization of the meetings, 
maintaining the records and communicating with all concerned. He/she will 
prepare the minutes of the meetings and get approval from the Chair before 
communicating to the researchers the decision of the IREC on the proposal 
submitted.  





• Meeting frequency: the IREC will meet at least four times in a calendar year 
to discuss operational issues and other business.  
• Meeting agenda and location will be communicated to all members at least 
five days before the day of the meeting. 
• Meeting quorum: at least 50% of the members plus a lay person physically 
present or by virtual communication (e.g. skype, video-conference, 
conference telephone call).  
• Special meetings: special meetings can be called by the Chair in the case of 
urgent matters. 
• Meetings for reviewing research proposals: The business of reviews will be 




• All proposals should be submitted in the prescribed application form(s). 
• All relevant documents, as specified in the application form, should be 
enclosed with the application forms. 
• The completed forms should   be   submitted by the Principal Investigator 
(PI) or the ILRI scientist responsible for the research through the research 
compliance portal or via ILRIResearchcompliance@cgiar.org . 
• All members (and reviewers) available will respond to the Secretariat with 
their comments and judgment on a) acceptability; b) required changes if not 
acceptable; c) need for meeting with the PI. 
• The Chair may request one or more members (and or reviewers) for an in-
depth review. 
• The Principal Investigator (PI) or the ILRI scientist responsible for the 
research should submit responses to review comments to the Secretariat.  
• If revision is needed, the revised document should be submitted within a 
stipulated period of time as specified in the communication. 
 
Review procedures  
• Proposal review meetings of the IREC will be conducted bimonthly 
(electronically and/or face-to-face). 
• The proposals will be sent to at least two members (lead reviewers) by the 
Secretariat at least 1 week in advance.  
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• Members with a conflict of interest will withdraw from review of a proposal. 
• Decisions will be taken by consensus after discussions, and whenever needed 
voting will be done.   
• Decisions may be to approve, reject or revise the proposals. Specific 
suggestions for modifications and reasons for rejection should be given. PIs 
may also be invited to a face-to-face meeting to provide clarifications.  
• Independent consultants/experts may be invited to offer their opinion on 
specific research proposals if considered needed by a majority of the IREC, 
but they will not be involved in decision making. 
 
Elements of review  
The following aspects will be considered in deciding whether or not approval is given: 
• Appropriateness of the scientific design and conduct of the study.  
• Approval of any other review committees (IACUC, IBC).  
• Justification of anticipated harms and risks versus anticipated benefits.  
• Selection procedure including inclusion/ exclusion, withdrawal criteria and other 
issues like advertisement for participant recruitment.  
• The means by which the study is explained and consent obtained 
• Management of research related injuries, adverse events and any compensation 
provisions.  
• The manner in which research results will be made available to research 
participants and the concerned communities  
• Protection of privacy and confidentiality.  
• Involvement of the community, wherever possible.  
• Plans for data analysis and reporting  
• Adherence to all regulatory requirements and applicable guidelines  
• Competence of investigators, research and supporting staff  




Expedited review  
• Expedited review may be carried out in urgent cases. The chair after 
discussion with members will decide if the review warrants expedition. 
• All revised proposals, unless specifically required to go to the main 
committee, will be examined in a meeting of identified members convened by 
the Chair to expedite decision making.  
  
Communicating the decision  
• Decision will be communicated by the Secretariat to the applicant by email 
within one week of the meeting at which the proposal is reviewed.  
• Suggestions for modifications, if any, will be sent to the PI by the Secretariat.  
• Reasons for rejection will be given to the applicant  
• The process of appeal will be communicated to the applicant 
 
Follow up procedures  
• A final report should be submitted to IREC at the end of study. 
• Any amendment to the protocol should be resubmitted for renewed 
approval using the ‘Minor Amendment form. 
• In case of premature termination of a study, the PI should notify the IREC 
within one month along with reasons for termination and with a summary of 
the data obtained so far.  
• Change of investigators / sites should be notified to the IREC using the Minor 
Amendment form.  
• Deviation(s) should be reported to IREC immediately. 
 
Record keeping and archiving  
The following document s will be kept 
• Operational guidelines for IREC 
• Curriculum Vitae (CV) of all members of IREC.  
• Copy of all study protocols with enclosed documents   
• Minutes of all meetings duly signed by the Chairperson.  
• Copy of all existing relevant national and international guidelines on research 
ethics and laws along with amendments.  
v05082021 
9  
• Copy of all correspondence with members, researchers and other regulatory 
bodies.  
• Final report of the approved projects.  
 
Documents will be maintained by the Secretariat and shall be physically archived for 5 






The International Livestock Research Institute (ILRI) is an international research institute 
and a member of the CGIAR. It has a head office in Kenya and other offices in East, 
West and Southern Africa, South and South East Asia. ILRI conducts research on 
reducing rural poverty, increasing food security, improving human health and nutrition, 
and ensuring more sustainable management of natural resources. 
 
The CGIAR is a global partnership that unites organizations engaged in research for a 
food secure future. CGIAR research is dedicated to reducing rural poverty, increasing 
food security, improving human health and nutrition, and ensuring more sustainable 
management of natural resources. It is carried out by 15 centers, of which ILRI is one, 
who are members of the CGIAR Consortium in close collaboration with hundreds of 
partner organizations, including national and regional research institutes, civil society 




2 Scope & mandate 
ILRI has constituted Institutional Research Ethics Committee (IREC) which will review 
and consider for approval all ILRI research activities with a view to safeguard the dignity, 
rights, safety and well-being of all actual and potential research participants and the 
wider community. Its scope covers, but is not limited to, all research involving human 
subjects. In addition, research not involving human subjects but with implications for the 
dignity, rights, safety and well-being of the wider community must also be subject to 
IREC review. 
The mandate of the IREC is to review all research activities to be conducted at ILRI or 
any other premises or field sites for which ILRI staff is responsible (scientifically and/or 
financially), and also to review any research activities which are led by ILRI scientists or 
have involvement of ILRI scientists as part of their duties as ILRI employees. This is 
irrespective of the funding agency or the place of research and irrespective of the scope 
or nature of the research. Where the research proposal is being led by another institute 
then ILRI IREC approval will not be granted unless the proposal has been approved by 
the research ethics committee of the lead organization.  
IREC ensures that the cardinal principles of research ethics (autonomy, beneficence, 
non-maleficence and justice) are followed in the planning, conduct and reporting of ILRI 
research. For this purpose, it covers the aspects of informed consent; harms, risks and 
benefits; distribution of these; management of these and provisions for appropriate 
compensations wherever required. It reviews research activity proposals before the 
start of the study and has developed procedures for monitoring the research 
throughout the study until, and after, completion. The committee also examines 
compliance with all regulatory and donor requirements, applicable guidelines and laws, 
including national (local) laws. 
The IREC will be established in accordance with the applicable laws and regulations of 
the country where ILRI head office is based. The IREC processes will also be in 
accordance with the applicable laws and regulations of the country in which the 
proposed research is to be carried out. The IREC will provide independent, competent, 
and timely review of the ethics of proposed studies.  
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3 IREC constitution 
3.1 Functions of IREC 
3.1.1 The IREC will consider applications and provide independent ethics review of 
research; 
3.1.2 The IREC will develop operational guidelines for ethics review and ethical 
conduct of research within the limits of national and international guidelines; 
3.1.3 The IREC will be available to researchers for consultation on ethical issues; 
3.1.4 The IREC will support and provide information and training in research ethics for 
researchers and others, both within and outside ILRI; 
3.1.5 The IREC will liaise with ethics committees of other institutions in matters of 
common interest; 
3.1.6 The IREC will promote community participation in research; 
3.1.7 The IREC will consult with individuals, communities and governments on ethics 
issues in countries where ILRI conducts research as appropriate; 
3.1.8 The IREC will keep up-to-date with best practice in research ethics. 
3.2 Composition of IREC 
3.2.1 The IREC will be multidisciplinary and balanced with respect to age and gender. 
It will include both people from outside and inside the institution; laboratory and 
non-laboratory scientists; people with knowledge of bio-medical and non-
biomedical fields; and people from the different countries where ILRI conducts 
research. 
3.2.2 There shall be 5-9 ILRI IREC reviewers whose mandate will only involve 
reviewing ILRI IREC applications. They will not be attending IREC meetings and 
will not have the right to vote.   
3.2.3 There should be adequate representation of age, gender, and community;  
▪ at least one third of the members male, and at least one third of the 
members female 
▪ the chairperson to have some training/experience in bioethics and leadership 
▪ at least two members who are medical clinicians, at least one of whom 
should be practicing or conducting clinical research 
▪ at least one member from outside the institute 
▪ at least one lay member 
▪ at least two members with research experience 
▪ one member with knowledge/understanding of the Kenyan law 
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3.2.4 Lay member means a member of IREC who is not: 
▪ currently, nor has recently been, a registered health practitioner (for 
example, a doctor, nurse, midwife, dentist or pharmacist); 
▪ an officer of, or someone otherwise employed by, any health board, health 
authority, the Ministry of Health, or medical school; 
▪ involved in conducting health research or who is employed by a health 
research agency and who is in a sector of that agency which undertakes 
health research; or 
▪ construed by virtue of their employment, profession or relationship, to have 
a potential conflict or professional bias in a majority of protocols reviewed. 
3.2.5 The IREC consists of a Chairperson, a Secretary, and up to fifteen members 
supported by a Secretariat.  
3.2.6 The IREC shall have the authority to co-opt a pro-tempore member with 
competence in a specialized field, onto the committee. The co-opted member 
shall assist in the review of complex issues which require expertise beyond or in 
addition to that available on the IREC but shall not participate in the final 
decision-making process on a particular research proposal or application. 
3.3 Role and Responsibilities of the Chairperson 
3.3.1 The IREC chairperson shall have training and experience in bio-ethics and 
experience in a leadership position. 
3.3.2 The responsibilities of the IREC chairperson shall be to: 
▪ provide leadership in establishing and implementing guidelines and standard 
operating procedures for the IREC;  
▪ review and approve the IREC meeting agenda; 
▪ ensure that all approved studies comply with the terms and conditions of 
approval for the duration of the research; 
▪ ensure that quorum is present and maintained during convened IREC 
meetings;  
▪ direct proceedings and discussions of the IREC meetings; 
▪ confirm and sign the minutes for each IREC meeting; 
▪ confirm and sign the annual report; 
▪ represent the IREC in explaining or discussing IREC decisions with research 
principal investigators (PI); 
▪ represent the IREC in discussions between ILRI and other institutions on 
issues related to research ethics; 
▪ assess conflicts of interest reported by other IREC members; 
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▪ coordinate activities designed to improve staff, and student, knowledge of 
sound ethics research practices; 
▪ assist the Director General ILRI in the recruitment of new IREC members. 
3.4 Role and Responsibilities of the Secretary 
3.4.1 The responsibilities of the IREC Secretary shall be to: 
▪ represent the IREC in discussions with the ILRI administration when so 
requested by the Chairperson; 
▪ facilitate the induction of new IREC members; 
▪ support activities designed to improve staff, and student, knowledge of sound 
ethics research practices; 
▪ ensure that submitted research proposals or applications are reviewed in a 
timely manner; 
▪ record minutes of meetings. 
▪ coordinate routine functions of the Secretariat and work closely with the 
IREC chairperson to provide for the efficient management of the IREC 
operations; 
▪ write specific correspondence to Principal Investigators (PI) as agreed upon 
at a convened IREC meeting; 
▪ prepare the annual report. 
3.5  The IREC Members 
▪ The IREC members shall be of diverse scientific background representative of 
the various research themes at ILRI and gender balanced i.e. no more than 
sixty percent (60%) of either gender. 
▪ The responsibilities of an IREC member shall be to: 
▪ conduct ethical reviews on submitted proposals  
▪ review IREC documents and materials prior to the IREC meeting and submit 
comments. 
▪ attend IREC meetings;  
▪ identify and facilitate the resolution of any issues for a given proposal. 
▪ participate in expedited reviews when called upon by the IREC Chairperson 
and provide written review comments. 
▪ participate in and conduct educational activities in research ethics. 
3.6 The IREC Reviewers 
▪ conduct ethical reviews on submitted proposals  




▪ participate in expedited reviews when called upon by the IREC Chairperson 
and provide written review comments. 
▪ participate in and conduct educational activities in research ethics. 
3.7 The IREC Secretariat 
3.7.1 The EOHS/Research compliance unit at ILRI shall serve as the secretariat to the 
IREC. 
3.7.2 The responsibilities of the IREC secretariat shall be to: 
▪ provide support to the IREC chairperson and members in the review 
process. 
▪ serve as an interface for the IREC, investigators, regulatory authorities and 
any other stakeholders on matters of research ethics. 
▪ oversee the accurate and timely processing, tracking and filling of all 
applications. 
▪ effectively communicate with investigators, IREC members, and other 
interested groups in a timely manner. 
▪ ensure that continuing review of research is conducted appropriately and in a 
timely manner. 
▪ maintain accurate records of IREC actions. 
▪ act as the initial point of contact with researchers. 
▪ maintain an accurate and comprehensive database of reviewed and approved 
research. 
▪ maintain accurate archiving systems that allows for access to open and closed 
studies. 
▪ update the IREC on any new information or regulation and changes affecting 
the IREC function or protection of research participants. 
3.8 Terms of Membership 
3.8.1 Appointments and termination 
▪ Members will be appointed by the Director General of ILRI. Members will 
receive a letter of appointment setting out the terms of membership. 
▪ New members will receive introductory training in the work of the IREC by 
the IREC secretariat within 3 months of joining the IREC.  
▪ Each member shall serve for a period of two (2) years following one (1) year 
of probation. The tenure may be renewed for additional terms at the 
discretion of the Director General. 
▪ The Director General of ILRI may terminate the services of, or disqualify, a 
member of IREC on grounds of misconduct, abuse of office, non-disclosure 
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of competing interests, inappropriate behavior, unprofessional Conduct and 
failure to abide by the terms of appointment. 
▪ Any member so terminated has a right of appeal to the ILRI Board of 
Trustees (BoT). 
▪ A member may resign from the IREC on his/her own volition. The member 
shall be required to submit his/her resignation in writing at least two (2) 
months prior to his/her anticipated end date to allow time to fill the vacancy 
that will exist as a result of his/her resignation. 
3.8.2 Requirements of members and reviewers 
▪ Members should be willing to make public their full names, profession and 
institutional affiliation. 
▪ Members shall be expected to declare any conflicts of interest which may 
arise or exist during their tenure on the IREC and for specific research 
activities. 
▪ Members will sign a confidentiality agreement at the beginning of their 
appointment regarding meeting deliberations, IREC applications, information 
on research participants, and related matters.  
▪ All IREC members shall be asked to undertake an online training provided by 
ILRI. These shall be repeated every two years as long as the member still 
serves on the committee. 
3.8.3 Reimbursement 
▪ Non CGIAR members (and reviewers) will be reimbursed for expenses 
incurred attending IREC meetings, conducting reviews and research site 
visits. The allowance shall be decided upon by the Director General and may 
be subject to change. The allowance will be publically available on the IREC 
website and annual report. 
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4 Application for ethics review 
4.1 Application Requirements 
4.1.1 The application requirements are as follows: 
▪ The procedures for submission of an application will be available on the ILRI 
research compliance website and by request to the IREC secretariat. 
▪ An application for ethics review of a research study shall be made by the 
Principal Investigator (PI) for that study.  
▪ All applications must be in English. 
▪ All applications for ethics review shall be submitted through the IREC 
mailbox (ILRIResearchcompliance@cgiar.org) or ILRI research compliance 
portal. 
▪ The IREC secretariat will check all submitted applications for completeness 
and correctness. Only complete applications shall be sent to IREC Members 
for review prior to the meeting. 
▪ All the relevant documents listed below in clause 4.2.2 must be submitted. 
▪ The average turnaround time from date of the meeting to final approval of a 
new application is estimated at three (3) to six (6) weeks, and can be more 
or less, depending on the quality of the application, the nature of the 
proposed research and the PI’s response time to the IREC’s review. 
4.2 Documentation 
4.2.1 All documentation required for a comprehensive review of the ethics of 
proposed research should be submitted by the PI for consideration by the 
committee. 
4.2.2 The documents for ethics review may include, but are not limited to: 
▪ Signed and approved research proposals involving ILRI scientists. 
▪ A completed and signed research compliance form and applicable IREC 
forms. 
▪ Any regulatory approvals and/or ethics review and approval from a research 
proposal partner institution. 
▪ The study protocol with supporting documents and annexes. 
▪ The curriculum vitae of the PI of the study. Material to be used (including 
advertisements) for the recruitment of potential research participants; 
▪ A description of the process used to obtain and document informed consent; 
▪ Written and other forms of information for potential research participants 




▪ Informed consent form templates in the language(s) understood by the 
potential research participants 
▪ Statement describing any compensation for study participation (including 
expenses and access to medical care) to be given to research participants; 
▪ A description of the arrangements for indemnity, if applicable; 
▪ A description of the arrangements for insurance coverage for research 
participants, if applicable; and research personnel. 
▪ All significant previous decisions (e.g., those leading to a negative decision or 
modified protocol) by other IREC’s or regulatory authorities for the 
proposed study (whether in the same location or elsewhere) and an 
indication of modification(s) to the protocol made on that account. The 
reasons for previous negative decisions should be provided; 
4.2.3 The documents required will vary on the nature of the proposed research. 




5 Review process 
5.1 Types of review 
5.1.1 There are different types of review depending on different needs and 
requirements: 
▪ Conditional review: when all the documentation and information is not available 
but a preliminary and conditional review is required 
▪ Final review: when all the documentation and information for a complete 
review is available and submitted 
▪ Expedited review: when a review is required within a justified short time 
5.1.2 In all types of review, all relevant documentation is provided and the Principle 
Investigator provides information on:  
▪ Anticipated benefits: 
▪ Anticipated risks and their management 
▪ Care and protection of research participants 
▪ Research activity details / protocol 
▪ Recruitment & involvement of research participants and informed consent 
▪ Protection of privacy & confidentiality 
▪ Feedback to communities & participants 
▪ Details on site facilities, equipment & skills of technical staff 
5.1.3 The review is on the basis of this information and documentation. IREC may 
request any additional information if information provided is insufficient for a 
comprehensive review. 
5.2 Review meetings 
5.2.1 Proposal review meetings of the IREC will be conducted electronically or 
physically once a month. 
▪ The proposals will be sent to members by the secretariat at least 1 week in 
advance. 
▪ Members with a conflict of interest will withdraw from review of a proposal. 
The conflict of interest should be reported to the chairperson within 1 week 
of the request to review and the reason recorded in the documentation of 
the review. 
▪ Decisions will be taken by consensus after discussions whenever possible. If 
consensus appears unlikely then the IREC will vote and a majority of at least 
one vote is required to carry the decision.  
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▪ Discussions will be documented and a copy signed by the Chairperson will be 
kept in electronic form for at least ten (10) years. 
▪ A minimum of four members (quorum) is required to make a decision on 
approval.  
▪ A decision may only be taken when sufficient time has been allowed for 
review and discussion of an application. 
▪ The quorum should not consist of one profession or gender only. 
▪ Discussions and acceptability will be synthesized within one week of the 
meeting and conveyed to applicants by email. 
▪ Decisions may be to approve, reject or revise the proposals. Specific 
suggestions for modifications and reasons for rejection will be given. A 
negative decision should be supported by clearly stated reasons. 
▪ Principal Investigators may also be invited to a face-to-face meeting to 
provide clarifications.  
▪ Independent consultants/experts may be invited to offer their opinion on 
specific research proposals if considered needed by a majority of the IREC, 
but they will not be involved in decision making. 
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5.3 Elements of the Review 
5.3.1 The IREC shall make a scientific evaluation of all research proposals, in particular 
the scientific design and conduct of the study. This will include; 
▪ Appropriateness of the scientific design and conduct of the study.  
▪ Approval of any other review committees (IACUC, IBC).  
▪ Justification of anticipated harms and risks versus anticipated benefits.  
▪ Selection procedure including inclusion/ exclusion, withdrawal criteria and 
other issues like advertisement for participant recruitment.  
▪ The means by which the study is explained and consent obtained 
▪ Management of research related injuries, adverse events and any 
compensation provisions.  
▪ The manner in which research results will be made available to research 
participants and the concerned communities  
▪ Protection of privacy and confidentiality.  
▪ Involvement of the community, wherever possible.  
▪ Plans for data analysis and reporting  
▪ Adherence to all regulatory requirements and applicable guidelines 
▪ Competence of investigators, research and supporting staff  
▪ Facilities and infrastructure of study sites  
▪ Further details on review of informed consent 
5.3.2 The IREC shall require investigators to obtain informed consent from each 
prospective study participant. In the case of children aged 12 years or younger, 
consent should be sought from parent/guardian 
5.3.3 Translation of all consent documents into relevant local dialects, either as a 
written document or at the time of administration of consent, by enumerators 
fluent in local languages and trained in the administration of consent forms.  
5.3.4 The IREC shall waive all or part of the requirements for documentation of 
informed consent, but oral consent may be obtained, if the research meets the 
following criteria: 
▪ The justification for the waiver is the signed consent is the only record 
linking the study participant to the research and is the primary risk of breach 
of confidentiality by the research. 
▪ The proposed plan for the protection of privacy is adequate. 
▪ The waiver will not affect the rights and welfare of the research participants. 
▪ The research participants will be given additional pertinent information after 
their participation. 
▪ The research presents no more than minimal and involves procedures for 
which consent would not normally be obtained outside the research context. 
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5.3.5 When research poses any non-negligible risks, harms or inconveniences to 
participants, then informed consent (required for all research involving people) 
requires more detailed review, as follows: 
▪ A full description of the process for obtained informed consent including the 
identification of those responsible for obtaining consent must be provided. 
▪ Provision for comprehensive (without technical terms) written and verbal 
information to be given to the research participants, and, when appropriate, 
their legally authorized representative(s). 
▪ A clear justification for the plan to include individuals who cannot consent, 
and a full account of the arrangements for obtaining consent or authorization 
for the participation of such individuals. 
▪ Provisions within the study that research participants will receive information 
that becomes available during the course of the study relevant to their 
participation. 
▪ Provisions made for receiving and responding to enquiries, concerns or 
complaints from research participants or their representatives prior to and 
during the course of a research study. 
5.4 Requirements of Informed Consent 
5.4.1 Informed Consent should follow the guidance provided by the WMA Declaration 
of Helsinki – Ethical Principles for Medical Research involving Human Subjects 
(http://www.wma.net/en/30publications/10policies/b3/). In summary, informed 
consent should provide the following: 
1. The aims of the study and the methods to be used 
2. The sources of funding and possible conflicts of interest 
3. The institutional affiliations of the researcher 
4. The anticipated benefits and potential risks 
5. The discomfort it may entail/the time it will take 
6. Any post-study provisions 
7. The right to abstain from participating, or to withdraw from it at any  
 time, without reprisals 
 
Additionally, it is required that the informed consent process includes the 
following: 
8. The opportunity to ask questions 
9. The way in which the study will be reported and shared 
10. The person to report any concerns about the study to i.e. someone from 
 the research team and someone from the ethics committee. 
11. Ensure and provide confirmation on the protection of confidentiality and 





5.4.2 Where a proposed participant is a minor (aged thirteen(13) to seventeen (17) 
years of age) who is possessed of sufficient understanding  to grant informed 
consent but is precluded from granting such consent solely on the grounds of 
age, the PI may obtain a written assent in addition to permission from a parent, 
guardian or any person in loco parentis. 
5.4.3 The IREC shall consider the following elements in its review of the assent 
process: 
▪ The procedure put in place for obtaining parental or guardian permission 
(consent) to have his/her child or children participate in the research. For 
those minors between fourteen (14) and seventeen (17) years of age, the 
language and syntax of the assent form may be written in a similar fashion as 
the parental or guardian permission form. 
▪ If the research proposed is determined to present greater than minimal risk 
and there is no direct benefit to an individual study participant, then parental 
permission from both parents/guardians shall be required unless one parent 
is deceased, unknown, incompetent, or not reasonably available, or when 
only one parent has legal responsibility for the care and custody of the child. 
▪ The parental permission and child assent is done in writing unless the IREC 
grants a waiver of documentation. 
▪ The ethics standards required in obtaining informed consent shall apply to 
assent.  
▪ The IREC shall waive the requirement for obtaining assent from a child if any 
of the following conditions apply in which case, consent from the parent(s) is 
sufficient: 
▪ The intervention stands to directly benefit the health and welfare of the child 
and is available only in the research setting. 
▪ The child is unable to provide assent due to age 12 years of age and below or 
a condition. 
▪ The research meets the same conditions for a waiver of informed consent in 
research involving adults. 
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5.5 Obtaining Consent from a Mature Minor 
5.5.1 The IREC shall consider a mature minor as any individual less than eighteen (18) 
years of age who is married, pregnant, a mother or a household head. 
5.5.2 A mature minor is permitted to give consent for him or herself and for their 
child/children but not allowed to consent on behalf of a sibling. 
5.6 Community Consideration 
5.6.1 During the evaluation of a research proposal or application, the IREC shall 
consider the following issues: 
▪ The potential impact and relevance of the research on the concerned 
communities from which the research participants are drawn. 
▪ The steps taken to consult with the concerned communities during the 
course of conducting the research and in disseminating research findings are 
transparent. 
▪ The measures taken to preclude the influence of the community on the 
consent of an individual. 
▪ The proposed community engagement process including public meetings, 
permission from the community elder or persons acknowledged as 
community representatives and where applicable, the establishment of a 
Community Advisory Board. 
▪ The extent to which the research contributes to capacity building, such as 
the enhancement of local healthcare systems and the improved capability of 
the community to respond to their welfare needs. 
▪ The provision for making available of any successful trial product to the 
participating communities on completion of the research and sustainability of 
any intervention.  
▪ The manner in which results of the research will be made available to the 
research participants and the concerned communities. 
▪ The consideration for cultural sensitivities and concerns. 
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5.7 Obtaining Consent from Vulnerable Populations 
5.7.1 The IREC shall require that exceptional consideration is given to protecting the 
welfare of particular vulnerable groups, such as children, pregnant women, 
neonates, fetuses, homeless youths, divisionally impaired persons, internally 
displaced persons, economically or educationally disadvantaged persons, 
marginalized social groups or individuals with terminal illnesses or prisoners. 
5.7.2 In its assessment of research involving vulnerable groups, the IREC shall require 
that: 
▪ The objective of the proposed research is to obtain knowledge relevant to 
the health (human and animal) or food security needs of the population 
under study. 
▪ The PI demonstrates that the research question cannot be answered if the 
study is carried out among a less vulnerable group. 
▪ The study participants are explicitly told that they are taking part in research. 
▪ The requirements for obtaining and documenting consent are tailored to the 
needs of the individual from the chosen vulnerable group. I.e. use of 
appropriate language, content of the consent/assent document and 
explanation of the procedures followed. 
▪ The risks from procedures and explanation of the procedures that do not 
proffer direct health-related of food security benefit are justified by the 
benefit and are similar to those from routine health, psychological tests and 
food security surveys. 
5.7.3 The IREC shall determine on a protocol-by-protocol basis the specific 
requirements for obtaining and documenting consent whenever any vulnerable 
groups are involved in research studies. 
 
5.8 Documentation of Consent 
5.8.1 The IREC shall require that informed consent be documented by use of written 
approved consent form unless a waiver is issued subject to conditions laid out in 




5.8.2 The consent form must be signed and dated by the research participant or 
research participant’s legally authorized representative at the time of consent. 
5.8.3 A copy of the signed and dated consent form should be given to the person(s) 
signing the consent form. 
5.8.4 When verbal consent is obtained from the research participant or research 
participant’s legally authorized representative, the IREC shall require the 
presence of a witness to the oral presentation. This summarized approved 
version of the consent form should be signed by witness and the person actually 
obtaining the consent. 
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6 Communicating IREC review decision 
6.1.1 The IREC Chairperson or Secretary will inform the PI, in writing, the outcome of 
ethics review within one week of the decision being made. 
6.1.2 The letter sent to the PI or applicant must articulate the reasons for the 
determination and clearly pointing out any further information that may be 
required. 
6.1.3 Any appeals to an IREC decision of disapproval or denial of ethics clearance to a 
proposed research study shall be handled as laid down in the section on conflict 
resolution.  
6.1.4 The letters for notification of ethics approval (conditional or final) shall include 
the following information: 
▪ The project ID and IREC reference number. 
▪ The name of the PI or PIs and institutional affiliation. 
▪ The exact title of the research proposal or application. 
▪ All documents submitted and reviewed by the IREC including the date and 
version numbers of each document. 
▪ The date the ethics approval was granted or rejected. 
▪ The type of approval given – Conditional or Final. 
▪ The duration of the approval.  
▪ The requirement that the research proposal or application must be carried 
out as stipulated in the proposal or application.  
▪ The requirement that any changes to the research study or its conduct be 
reported to IREC prior to initiation.  
▪ The requirement that any unanticipated adverse events that might affect 
continued ethics approval of the study or if the study is terminated for any 
reason be reported to the IREC.  
▪ The requirement for the PI or applicant to apply for new scientific and ethics 
approval for substantially modified or revised research protocols.  
▪ The requirement for the submission of study report as prescribed by IREC 
and a final report at the completion of a study. 
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6.1.5 Where changes are required prior to approval the IREC Chairperson or 
Secretary shall detail these and also outline any additional information or 
clarification on specific issues necessary for the IREC to make its final decision. 
The IREC Chairperson or Secretary shall do this on one occasion, followed by 
two (2) reminders. The 120 days response period shall start from the date the 
initial notification was sent to the PI.  
6.1.6 The letter for notification of deferments shall include the following information: 
▪ The project ID and IREC reference number. 
▪ The name of the PI or PIs and institutional affiliation. 
▪ The exact title of the research proposal or application. 
▪ All documents reviewed by the IREC including the date and version numbers 
of each documents. 
▪ The IREC Secretary shall specify the issues raised by the IREC and detail the 
information to be furnished by the PI or applicant for review to continue. 
6.1.7 The letter for notification of disapprovals shall include the following information: 
▪ The project ID and IREC reference number. 
▪ The name of the PI or PIs and institutional affiliation. 
▪ The exact title of the research proposal or application. 
▪ All documents reviewed by the IREC including the date and version numbers 
of each documents.  
▪ The IREC Chairperson or Secretary shall describe to the PI or applicant the 
basis for the disapproval and modification to the research proposal required 
for IREC to re-consider its views on the proposed study.  
6.1.8 The Program Leader, Deputy Director General and any other relevant person 
shall also be notified of the disapproval.  
6.1.9 The IREC Chairperson or Secretary shall inform the PI or applicant that he or 
she may request the IREC to consider a new application if additional or novel 
information becomes available or if changes are made to the proposed study that 
would address the IREC’s initial concerns.  
6.1.10 Letters to Principal Investigators 
▪ The letters shall be signed by the IREC Chairperson or Secretary.  
▪ Two (2) copies of each letter shall be produced. One (1) of the letters shall 
be sent to the relevant PIs. The other one (1) letters shall be filled in the 




▪ The letter shall request a response from the PI or applicant within twenty 
(20) working days from the date of the letter. If the PI does not respond, a 
first reminder shall be sent to the PI by the IREC Secretary. Should the PI not 
respond to the reminder, a second reminder shall be issued after which a 
notice of removal of the items from the IREC meeting agenda shall be sent to 
the PI. The letter shall request that the PI or applicant directs his or her 
responses to the IREC Secretariat. 
▪ The PI or applicant will be requested to remit revised proposal or application 
and other study documents requested to IREC secretariat through IREC 
Mailbox. 
6.1.11 Handling a response from a PI or applicant 
▪ A response from a PI shall include an explanatory cover email with an 
attached revised research proposal highlighting the revisions made or any 
additional information, if applicable. 
▪ Upon receipt of a response from the PI, the IREC secretary shall review the 
response to determine if all the revised or new documents have been 
received and each question raised by the IREC has been adequately 
addressed. 
▪ If the PI or applicant disagrees with the IREC’s interpretation or request, 
then he/she must explain his/her reasons. The response will be included in 
the next available IREC meeting’s agenda for further review. 
▪ Where outstanding issues have been resolved or adequately addressed, the 
IREC Secretary shall proceed to issue an administrative approval as agreed 
upon earlier by the convened IREC. The administrative approval shall be 
reported at the next convened IREC meeting. 
▪ If a research proposal or application had been deferred, then the response 
documents shall be placed on the next available IREC meeting’s agenda for 
consideration. The PI may be requested to attend an IREC meeting for 
further discussions. The decision on a PI’s attendance shall be decided upon 
at a convened IREC meeting. 
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▪ If a study has not been granted ethics clearance and the PI would like the 
IREC to reconsider its decision on the proposed study, then he//she may put 
the request in writing and address it to the IREC Chairperson. The IREC 
Chairperson shall review the response and if he/she is in agreement that new 
information has been provided by the PI that address IREC’s concerns, the 
response and the revised study proposal shall be reviewed by the full 
committee at the next scheduled IREC meeting. If the IREC Chairperson 
finds the response unsatisfactory, then the convened IREC and the PI shall be 
so advised. 
▪ All responses from a PI or queries shall be acted upon with two (2) working 
days of receipt by the IREC Secretariat. 
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7 Post decisions processes 
7.1 Protocol amendment 
7.1.1 An amendment is defined as any change to the research project, such as: 
▪ Recruitment-number of study participants, recruitment methods, recruitment 
materials, selection of study participants etc. 
▪ PI, co-PI, students or research coordinators or other investigators on the 
study. 
▪ Research sponsor or funding agency. 
▪ Study site(s). 
▪ Study design including but not limited to study population, methodology, 
study procedures, sample size, equipment, intervention or follow-up 
procedures. 
▪ Privacy of information or confidentiality of research participants. 
▪ Data collection, storage, custody, or destruction procedures. This includes 
revisions to approved questionnaires/surveys or development of a new 
questionnaire/study instrument. 
▪ Informed consent/assent-forms, procedures, new or additional information. 
▪ Terms of compensation. 
7.1.2 Conflict of interest(s). 
7.1.3 All Principal Investigators shall be required to submit any proposed changes 
to a previously approved study with a justification for the change to the IREC for 
review prior to initiation. The only one exception to this rule shall specifically be 
where the change is necessary to eliminate apparent immediate danger/risk to 
the research participants. In such instances, the principal investigator must 
submit a report to the IREC explaining the protocol deviation. 




7.2 Monitoring of Approved Research 
7.2.1 The IREC shall monitor the progress of all research projects for which it has 
granted ethics approval to ensure they are complying with conditions of 
approval. 
7.2.2 Ethics project monitoring shall be done by the IREC secretariat as defined during 
project approval.  
7.3 End of Project/Research Report 
7.3.1 IREC approved projects close report shall be reviewed at scheduled IREC 
meeting. The IREC shall review the following items of project close reports: 
▪ The summary of all research activities clearly demonstrating that all study 
activities including follow-up procedures are completed. 
▪ The study results and dissemination reports. 
▪ Copies of all publications arising from the study. 
▪ The plan (or not) to refer back to the research records to verify research 
data, if applicable. 
▪ An assurance of the destruction of each study participants’ identifiers, 
whether direct or indirect. 
▪ An assurance that any surplus investigational agent has been destroyed. 
▪ An assurance that any surplus investigational agent has been destroyed unless 
the study protocol stipulated that the specimen(s) in question would be 
subject to long term storage and future research.  
7.3.2 The IREC shall evaluate the close report and if the committee concurs that the 
research study is ready to close, the IREC Secretary shall inform the PI, in 
writing, that the study status is noted as “closed”. 
7.3.3 The IREC secretary shall communicate to the PI within five (5) working days of 
the meeting at which the report was discussed. 
7.3.4 All closed study hard-copy files shall be retained in the IREC Office for three (3) 
years from the date of closure. After three (3) years, the closed files shall be 
indexed, boxed, and sent to the ILRI archives. Electronic copies of the same 




8 IREC meetings 
8.1 IREC Meeting Agenda 
8.1.1 The IREC secretariat shall prepare the agenda for each scheduled meeting. The 
following agenda format shall be used: 
▪ Attendance /apologies 
▪ Confirmation of minutes of the previous meeting. 
▪ Matters arising from previous minutes. 
▪ Declaration of conflict of interests 
▪ Update on review of new proposals or applications. 
▪ Update on review of amended protocols. 
▪ Review of final study reports. 
▪ Review of safety reports. 
▪ Protocol déviation and/or violation notifications. 
▪ Any other business. 
▪ Date of next IREC meeting. 
8.1.2 The IREC secretary will complete and close the agenda ten (10) working days 
prior to the IREC meeting date. If the deadline falls on a weekend or holiday, the 
agenda items shall be received up to 5.00pm the next business day. 
8.2 Meeting Requirements 
8.2.1 The IREC meeting requirements are as follows: 
▪ The IREC shall hold at least four (4) scheduled meetings in each calendar 
year every second Thursday of the meeting month. 
▪ The schedule for the IREC meetings shall set out the dates, times, venues of 
meetings and the closing date for applications to each meeting. 
▪ The IREC chairperson may convene special ad-hoc meetings within three (3) 
to five (5) working days’ notice, to provide expeditious review of research 
proposals or applications, address concerns regarding the rights and welfare 
of study participants, review unanticipated problems or non-compliance 
issues. 
▪ The IREC members shall receive final notification of the meeting, the agenda 




▪ The minutes of each meeting shall be recorded and confirmed at the next 
convened IREC meeting with the signature of the chairperson appended on 
the last page of the document. 
▪ The IREC chairperson may invite the PI to an IREC meeting to present their 
proposal or to elaborate on specific issues or to offer clarifications. 
▪ All the IREC meetings shall be directed by the chairperson; if the chairperson 
is not available, an alternate chairperson will be appointed by the chairperson 
▪ No IREC meeting shall be held or proceed without a quorum, present or 
attending virtually, constituting nine (9) IREC members including one member 
from the IREC secretariat.  
▪ No quorum should consist entirely of members of one profession or one 
gender; a quorum should include at least one member whose primary area of 
expertise is in a non-scientific area, and at least one member who is 
independent of the institution/research site. 
▪ If a quorum is lost during a meeting the IREC shall not take votes or make a 
decision on a research proposal or application until the quorum is restored. 
If quorum cannot be established the meeting shall be adjourned and re-
scheduled. 
▪ An IREC member should attend at least 2 of the scheduled meetings each 
calendar year. Failure to attend the required minimum may lead to 
termination of the appointment to the committee. 
8.2.2 The attendance of a principal investigator will be expected under the following 
circumstances: 
▪ The IREC chairperson or IREC secretary shall invite a PI, in writing, to attend 
the meeting at which his/her application requires further clarification or 
discussion. The PI shall not be required to make any formal presentation of 
the study at the meeting, unless requested to do so. 
▪ The purpose of invitation shall be to enable the PI respond directly to 
requests from the committee for further information, clarification or 
reassurance. 
▪ The attendance of the PI shall not be prescriptive and consideration of the 




▪ The IREC holds closed sessions meetings therefore the invited PI or applicant 
will be requested to wait outside the meeting room until he or she is called 
in for discussions on his or her research proposal or application, the PI can 
join in virtually, in this case the IREC shall call the PI. The invited PI may 
come or join virtually along to the IREC meeting with any additional study 
team members but this arrangement must be made between the PI and the 
study team. 
▪ Where the PI is unable to attend, it shall be acceptable for another key 
investigator or collaborator to substitute. A representative of the sponsor 
shall not be eligible to attend in the place of the PI, but the IREC chairperson 
may allow this in exceptional circumstances but must be accompanied by a 
key investigator. 
8.2.3 All attempts will be made by the IREC to resolve issues of concern at the 
meeting. 
8.2.4 When further consideration needs to be given to an application after the 
attendance of the PI, his or her re-attendance shall be deemed useful in 
formulating a conclusive decision on his/her application. However, the PI shall 
not be present during the confidential discussions and final assessment of the 
applications by the committee. 
8.2.5 Attendance of an observer will be under the following circumstances: 
▪ An observer(s) may be invited to attend IREC meetings subject to written 
invitation setting out the terms under which observer status is permitted. 
This includes: signing of a confidentiality agreement, detailing the purpose of 
the attendance and the concurrence of the IREC members on the meeting to 
be attended by the observer(s). 
▪ An observer(s) shall have no vested interest in the scientific or management 
responsibility for any applications being considered at the IREC meeting. 
▪ The chairperson shall verbally inform any investigator who attends the 
meeting whenever an observer is present. The investigator shall be given the 
opportunity to object to or approve the presence of any observer. If there is 
an objection, the observer shall be requested to leave the meeting room 
during the discussion of that item of the agenda. 
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▪ IREC meetings, or parts of meetings, may also be attended from time to time 
by representatives from ILRI management committee. The arrangements for 
such attendance shall be discussed and agreed upon in advance with the IREC 
chairperson and shall be subject to the terms and conditions set for the 
attendance of an observer. 
▪ The attendance of an observer or observers shall be recorded in the 
minutes. 
8.3 Meeting Minutes 
8.3.1 The IREC Secretariat shall be responsible for preparing and maintaining detailed 
minutes of all IREC meeting. 
8.3.2 The minutes of the meetings shall include the following items: 
▪ Attendance, including members present, absent and apologies received. 
▪ Quorum shall be documented (number and composition). 
▪ Any conflict of interest related to each protocol reviewed during the 
meeting. 
▪ The names of IREC members who abstained from participating in the 
deliberations and in taking a vote on a specific research proposal or 
applications due to competing interests. 
▪ The time meeting was initiated and closed. 
▪ The approval of previous meeting minutes. 
▪ The resolution of action items from the previous meetings. 
▪ All reports considered during the meeting 
▪ A summary of the discussion of dissenting issues and their resolutions or 
required action. All dissenting opinions will be noted in the minutes but no 
particular view will be ascribed to a particular IREC member. 
▪ The names of investigators or applicants who attended the meeting or have 
been invited to attend a particular IREC meeting discussion on their research 
proposals or applications. 
▪ The date and signature of chairperson. 
8.3.3 The minutes shall be produced within five (5) working days following the 
relevant meeting and shall be verified by the chairperson. The minutes shall be 
circulated to all IREC members for review. 
8.3.4 The final minutes shall be sent out to members within five (5) working days and 




9 Expedited reviews 
9.1.1 All revised proposals, unless specifically required to go to the main committee, 
will be examined by identified members convened by the chairperson to 
expedite decision making. 
9.1.2 Expedited review may also be taken up in cases of institutional proposals 
requiring urgent review. 
9.1.3 Expedited review proceeding will be documented as all other IREC meetings and 
the decision communicated as other IREC decisions. 





10 Review of research with ethical implications but not involving human 
subjects 
10.1 Research on Cloning or Genetically Modified Organisms 
10.1.1 Biosafety aspects of genetic research studies at ILRI are reviewed by Institutional 
Biosafety Committee (IBC) and welfare aspects under the Institutional Animal 
Care and Use Committee (IACUC). 
10.1.2 IREC will review ethics considerations of the projects. This shall follow the 
procedure for reviewing applications. 
10.1.3 IREC shall only review such applications once IBC approval has been granted for 
the use of rDNA. 
10.2 Research Involving Animals 
10.2.1 Use of animals in research at ILRI is reviewed by Institutional Animal Care & Use 
committee (IACUC). 
10.2.2 IREC reviews ethics considerations of applications only. This shall follow 
procedure of review of ethics applications. 
10.2.3 IREC shall only review such applications once IACUC approval has been granted 




11 Charges for review 
11.1.1 At the time of writing these guidelines, the IREC does not require any fees for 
review of research proposals or any applications. However, this policy is subject 
to periodic revision. 
11.1.2 The fee structure will be transparent and will be posted on the ILRI internet and 





12 Adverse events 
12.1.1 The IREC shall consider an adverse event as any unfavorable or unintended sign, 
symptom or disease, including an abnormal laboratory finding temporarily 
associated with the use of an investigational treatment or procedure regardless 
of whether or not a causal relationship with research is considered likely. 
12.1.2 Any adverse event must be reported to the IREC via email 
(ILRIResearchcompliance@cgiar.org) within twenty four (24) hours after the PI 
becomes aware of the event. The hard copies of the report must be forwarded 
to the IREC secretariat within three (3) working days of the initial notification. 
Follow-up reports shall also be submitted as soon as information becomes 
available. 
12.1.3 The written safety report should be addressed to the IREC Chairperson and 
submitted through the IREC secretariat. 
12.1.4 The reporting should include the PI’s opinion on the relationship of the adverse 
event with participation in the study. 
12.1.5 The IREC shall review the adverse event at its next scheduled meeting at which a 
determination shall be made on the appropriate course of action.  
12.1.6 The IREC chairperson shall take action on adverse events considered serious 
and requiring immediate attention and shall be brought for ratification at the 
next convened IREC meeting. 
12.1.7 The PI shall be required to submit follow-up report on the information received, 
if the report suggests that the severity of an event has increased, or suggest the 
event is more likely to be related to the study than initially thought, or seems to 
affect the rights and welfare of current study participants. 
12.1.8 The IREC shall communicate to the PI, in writing, its decision or its intention to 
take a particular action within five (5) working days of the date at which the 
decision was made. 
12.1.9 The following definitions of the relationship of an adverse event with an 
investigational procedure are issued as a guide: 
▪ Not related: The adverse event is clearly not related to the investigational 
procedure. Another case of the event is plausible. 




▪ Probably related: The adverse event is likely related to the investigational 
procedure. 
▪ Definitely related: The adverse events is clearly relate to the investigational 
procedure. 
13 Protocol deviation and/or violation 
13.1.1 The IREC shall consider a protocol deviation as any failure to adhere to the 
defined procedures outlined in the protocol version previously approved by the 
IREC. 
13.1.2 The IREC shall consider a protocol violation as any planned or inadvertent 
changes that may or may not impact safety of study participants, affect the 
integrity of study data, and/or affect study participants’ willingness to participate 
in the study previously approved by the IREC. 
13.1.3 The reporting should be made to the IREC Chairperson, and copied IREC 
Secretariat within five (5) working days of the deviation or violation. 
13.1.4 The IREC shall review the deviation or violation report at its next scheduled 
meeting, at which a determination will be made on the appropriate course of 
action or the incident, will be noted if the remedial measures taken by the PI are 
satisfactory and appropriate. 
13.1.5 The IREC Secretary shall communicate to the PI, in writing, the decision of the 
IREC or its intention to take a particular action within two (2) working days of 
the meeting at which the decision was reached. 
13.1.6 The IREC shall have the authority to suspend ethics approval for any research 
where it is of the opinion that the research is not being or can no longer be 
conducted in accord with provisions of the approved protocol. 
13.1.7 The IREC may also suspend the ethics approval of a research study when there is 
serious or continuing non-compliance with applicable research regulatory 
requirements. 
13.1.8 The chairperson shall request, in writing, for immediate, temporary suspension 
of enrolment of new study participants or of continued participation of 
previously enrolled study participants, pending review of the situation in the next 




13.1.9 The convened IREC shall review the suspension report. The actions the IREC 
may take include but are not limited to: 
▪ Require minor or major changes in the research procedures and/or consent 
documents or process. 
▪ Modify current approval period. 
▪ Require monitoring of the research. 
▪ Require monitoring of the consent process. 
▪ Suspension of enrolment of new study participants. 
▪ Require notification of the enrolled participants when such information may 
influence their willingness to continue participating in the research. 
13.1.10 The IREC shall assign reasons for its action and promptly advise the PI in 
writing, of such suspension and the necessary steps to be taken. 
13.1.11 The suspension shall occur within five (5) working days of the date the IREC 
makes the determination and no later than five (5) working days after the PI 
has received the notice of suspension. 
13.1.12 The PI may not resume a suspended study without ethics approval from the 
IREC. 
13.1.13 The IREC Chairperson shall inform the head of department or the regional 
representative of ILRI affiliated Institution, responsible Deputy Director 
General and Director General ILRI of the suspension of any ethics approval.  
13.1.14 The IREC has the authority to terminate the approval for which it has granted 
ethics clearance when: 
▪ There is misconduct by a PI or any investigators on the study that is evidently 
confirmed. 
▪ The research presents excessive risks to research participants i.e. the actual 
risk-benefit status of the study is not consonant with the predicted risk-
benefit ratio prior to the implementation of the study. 
▪ A PI or team members fail to comply with research regulations. 
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13.1.15 The IREC Chairperson shall request an immediate termination of further 
accrual of new study participants or of continued participation of previously 
enrolled study participants whenever any of the conditions outlined in clause 
13.1.14 apply. 
13.1.16 The IREC Chairperson shall convene a special meeting at the earliest 
convenience to review the termination report. The actions the IREC may take 
include but are not limited to: 
▪ Request for a report summarizing the study protocol and detailing the 
accrued data. 
▪ Submission of the study results at the time of termination. 
▪ Establishment of a mechanism for an extended follow-up to monitor safety 
issues. 
▪ Require the PI to debrief study participants of the termination and also notify 
those study participants who have completed study activities. 
▪ Compensation of study participants, where applicable. 
▪ A requirement that the principal investigator and the study team members 
undertake research ethics and GRP re-training. 
▪ Perform an audit or other active studies of the Principal Investigator. 
13.1.17 The IREC shall assign reasons for its action and promptly advise the PI and study 
sponsor, in writing, of such termination and the measures needed. 
13.1.18 The termination shall occur within five (5) working days of the date the IREC 
makes the determination and no later than five (5) working days after the PI 
has received the notice of termination. 
13.1.19 The PI may not resume a terminated study. 
13.1.20 The IREC chairperson shall inform the study sponsor, Head of Department or 
Regional representative of ILRI affiliated Institution, responsible DDG, Director 
General ILRI and the NACOSTI CEO/Secretary of the termination or 




14 Conflict resolution and rights of appeal 
14.1 Complaints on the Conduct of Research 
 
Complaints concerning the conduct of research will be dealt with as follows: 
14.1.1 The IREC secretary shall be the contact person for handling complaints regarding 
the conduct of a research study. 
14.1.2 The name and contact information of the IREC Secretary shall be included in all 
informed consent/Assent Documents for all studies. 
14.1.3 Any individual with a complaint about the conduct of a study will be required to 
bring the complaint to the attention of the IREC Secretary. The IREC secretary 
shall notify the IREC Chairperson of the compliant or concern. 
14.1.4 The IREC will document, in writing, the basis of the complaint or concerns. 
14.1.5 The IREC shall review all allegations of serious or continuing non-compliance 
with IREC requirements. Non-compliance involves conducting research in a 
manner that disregards or violates the IREC’s regulations and/or a protocol. 
14.1.6 The IREC shall initiate an investigation of the complaint or concern. The 
investigation will take no longer than ten (10) working days from the date of 
receipt of the complaint or concern. 
14.1.7 Upon receipt of such allegation, the IREC chairperson will send a written notice 
of the allegations to the PI, within five (5) working days from the date of IREC 
review. The PI shall be required to respond to the claim. 
14.1.8 The IREC will then proceed to review both the allegation and response received 
from the PI and other relevant information upon which the committee may 
recommend: 
▪ Dismissal of the allegation or compliant as unjustified. 
▪ Referral of the matter to another more appropriate process or authority 
within the institution or other relevant authority for resolution. 
▪ Resolution through corrective or educational measures where the violation 
is minor or inadvertent. 
▪ The launch of a formal IREC investigation where the allegation or compliant 
appears founded and is of a serious nature. 
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14.1.9 Should the IREC opt for a formal investigation, it may rely on all information 
gleaned from the initial inquiry, obtain documents and other records relevant 
to the investigation and may interview any person(s) with information relevant 
to the complaint. The PI under investigation shall be given an opportunity to 
submit written comments and to appear before the investigation committee on 
at least one occasion before the committee issues a report of its findings.  
14.1.10 The actions the Committee may take with respect to the investigation include 
but are not limited to: 
▪ Dismissal of the complaint as unjustified. 
▪ Corrective or educational measures. 
▪ Frequent monitoring of research activities. 
▪ Recommend frequent reporting by the researcher of his/her research 
activities. 
▪ Recommend restrictions on research practice. 
▪ Suspension of approval of one or more of the investigator’s studies. 
▪ Termination of approval of one or more of the investigator’s studies. 
▪ Referral of the matter to other ILRI committees for possible further review 
and action by those bodies. 
14.1.11 The IREC may take such measures as necessary to protect the identity of 
person(s) making allegations and may liaise with ILRI administration to protect 
complainants or informants from any retaliatory actions. The complainants or 
informant shall be reassured of their protection to the extent permitted by 
law. 
14.1.12 The IREC chairperson will notify the PI and the complainant or informant in 
writing the results of the inquiry and reasons for such decision. 
14.1.13 The IREC chairperson shall notify the Head of Department or Regional 
representative of ILRI affiliated Institution, responsible DDG, Director General 
ILRI and the Executive Secretary of the NACOSTI of any unauthorized 




14.2 Appeals to IREC Decisions 
14.2.1 Any appeals to an IREC decision should be filed by the PI. 
14.2.2 Any PI with a complaint regarding the IREC’s disapproval of their proposed 
research study will be required to direct the matter to the IREC chairperson in 
writing, detailing the basis of the complaint or concern. 
14.2.3 The PI may also refer the compliant to the Director General ILRI or to the 
NACOSTI CEO/Security as guided by the NACOSTI appeal policy. 
14.2.4 The IREC Chairperson shall provide the Director General ILRI or Executive 
Secretary of the NACOSTI with all the necessary information about the 
proposed research study which shall include: 
▪ The complaint. 
▪ All documents pertaining to the proposed study that was reviewed by the 
IREC. 
▪ A report detailing the IREC’s deliberation on the research proposal. 
14.2.5 The director ILRI, in consultation with the relevant committees, shall review the 
documents provided by the IREC chairperson to determine if further 
investigation is warranted. If the Director General finds that there is no need for 
further investigation, the IREC’s decision shall be upheld. The Director General 
ILRI shall inform the IREC and the PI, in writing, of the decision. If it is 
determined that the appeal deserves further investigation, then an independent 
Appeals committee will be constituted to undertake review of the petition 
documents. 
14.2.6 In conducting its review, the Appeals committee shall consider whether the IREC 
acted in compliance with: 
▪ The National guidelines for research clearance and conduct of research. 
▪ The IREC Terms of Reference. 
▪ The ILRI Research Compliance Policy. 
▪ The IREC Operating Guidelines 
14.2.7 The Appeals Committee will notify the Director General ILRI, in writing, the 
outcome of the investigation which may be: 
▪ Dismissal of the complaint or concern, in which case the decision will be 
final. The Director General ILRI shall communicate this determination to the 
IREC and the PI. 
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▪ Referral back to the IREC for re-consideration with new information 
obtained by the Appeals Committee. If the appeal file is referred to the IREC 
for further evaluation, the IREC’s decision on the matter shall be final. The 
IREC Chairperson shall communicate to the PI and the Director General 
ILRI, in writing, within two (2) working days of the meeting at which a final 




















15 Ensuring confidentiality of IREC applications and proceedings 
15.1.1 The IREC shall have strict regard to confidentiality of records and of the 
decisions which are based on consensus or vote of members. 
15.1.2 The IREC members and staff of the IREC Secretariat shall be required to sign a 
confidentiality agreement upon appointment (Appendix B: Members Confidentiality 
Statement). 
15.1.3 All IREC documents shall be delivered to the prospective IREC member’s offices 
by the IREC Secretariat staff. 
15.1.4 At the end of each IREC meeting, all members shall be required to return their 
meeting files to the IREC secretariat. If an IREC member chooses to retain any 
document for his/her interest, he/she may do so but shall assume full 
responsibility for maintaining its confidentiality and its safe disposal. 
15.1.5 The meeting documents shall be disposed off within two (2) working days of the 
prospective IREC meeting. 




16 Requests for shipment or secondary use of samples 
16.1 Shipment of Samples 
16.1.1 Shipment of human biological samples and specimens is handled by EOHS/ 
Research Compliance Unit. 
16.1.2 All request for shipping human samples should be sent to EOHS/Research 
Compliance Unit by sending an email to ILRIResearchcompliance@cgiar.org . 
Processing of permits to move research materials to and out of ILRI shall be as 
per ‘Research Material Movement Standard Operating Procedure’. 
16.1.3 Storage of samples at ILRI shall be as per ILRI research refrigerator and freezer 
management guidelines. 
16.2 Secondary Use 
16.2.1 The IREC shall review all applications requesting use of archived human samples 
and specimens at its next available meeting provided the applications are 
received by the IREC Secretariat on or before the deadline for submission. 
16.2.2 Requirements: 
▪ A disclosure of the name of the PI for each of the studies from which the 
samples will be obtained. 
▪ A disclosure of the study or studies (give title and any study identification 
numbers) from which the samples were derived. 
▪ The specific purpose for which the samples are to be used. 
▪ Evidence that scientific review of the proposed study has been done to 
ascertain the merit in conducting the study. 
▪ The number and types of samples to be obtained from each study. 
▪ An assessment on the integrity of the archived samples to be used to ensure 
that the samples in question are suitable for use in the proposed study and 
will yield meaningful results. 
▪ An analysis on the limitation of the new study presented by the criteria for 




▪ A disclosure of whether the PI of the new study can link the specific samples 
to the individuals or the community from which the samples were obtained 
either directly or indirectly through an existing code, coding system or by a 
combination of variables that can result in identification of an individual or 
community or whether anonymised samples (i.e. stripped of all identifiers) 
will be used. 
▪ The arrangements for privacy protections where it is possible to de-identify 
the samples. 
▪ The identification of the samples must be limited to the extent necessary to 
achieve the study objectives. 
▪ A detailed description of the agreements (MTA) between the investigators 
on transfer and storage of the biological sample, ownership of data, findings 
or patents. 
▪ A copy of the previously approved consent document used for the initial 
collection of the biological specimen. 
16.2.3 For samples collected and archived without notification of future potential uses, 
Institutional consent shall be acquired through the responsible Deputy Director 
General thereafter IREC may provide surrogate consent for their use provided 
that the samples will be anonymised or coded and the research is being 
conducted in line with the objectives of the initial study for which the samples 
were collected. If the study is likely to produce information relevant to the 
health or well-being of the person who gave the sample, the IREC shall request 
that appropriate follow-up be done where it is possible to re-contact the study 
participants provided that consent was given for future contact. 
16.2.4 The IREC’s discussions on the application shall be recorded in the minutes. 
16.2.5 The IREC Secretary shall communicate to the PI, in writing, the decision of the 
IREC on the application within two (2) working days of the meeting at which the 
decision was reached. 
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17 Archiving IREC documents 
▪ All documentation and communication of the IREC shall be dated, filed, and 
archived according to written procedures. The IREC Secretariat shall be 
responsible for accessing and retrieving of the various documents, files, and 
archives in electronic form.  
▪ All hard-copy documents received by the IREC shall be retained by the IREC 
Secretariat for three (3) years following completion of a study and then sent 
to the ILRI archives for storage up to a period of fifteen years or indefinitely. 
The criteria for length of storage shall be guided by ILRI’s archiving policy. 
▪ Electronic documentation and communication shall be stored on back-up 
servers aeternum (‘forever’) and in such a way that they remain compatible 




18 Annual reports 
18.1.1 The report should comprise the following: 
▪ A list of all protocols reviewed during the year. It should include the 
following information: - 
* research title, 
* principal investigator and his/her qualifications, 
* co-investigators and their qualifications, 
* institution where the research is to be/has been undertaken, 
* date of approval. 
▪ Any changes in IREC membership or guidelines for operation, or other 
substantive changes which the committee or its Chair feels should be noted. 
▪ A summary of other activities of the IREC including training, monitoring and 
evaluation of approved research projects. 
▪ Any areas of review which caused difficulty for the IREC in making a decision 
on any particular protocol(s), and any questions on policy or other matters 
which the committee may wish to put forward. 
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19 Amending the IREC guideline document 
19.1.1 The proposal for an amendment to a section or sections of IREC guideline 
document shall be submitted to IREC Secretariat through the Research 
Compliance portal or via ILRIResearchcompliance@cgiar.org.  
19.1.2 IREC members shall review the amendment proposal and make comments or 
raise concerns which shall be sent to the Secretariat. The Secretariat shall 
compile all comments from members for discussion at a convened meeting. Only 
when approved by the IREC will the proposal be referred to the ILRI 
Management Committee/ Board by the IREC Chairperson for review. 
19.1.3 The ILRI Management Committee/ Board shall table the suggested amendment 
and notify the IREC outcome of its deliberation. If the amendment is approved, 
the section or sections shall be so amended by the IREC Secretariat. The 
amendment shall be ratified at the next scheduled IREC meeting and will take 
effect from the date of that IREC meeting. 
19.1.4 The ILRI Management Committee / Board may also put forward a proposal for 
an amendment to a section or sections of IREC guideline document. The 
amendment proposal shall be distributed to all IREC members for their 
consideration. 
19.1.5 The proposed amendment will then be discussed at the next scheduled IREC 
meeting. The IREC shall then provide its decision on the proposed amendment 
to the ILRI Management Committee / Board. 
19.1.6 The ILRI Management Committee / Board shall consider the advice of the IREC, 
and if in agreement, the section or sections will be so amended by the IREC 
Secretariat and will take effect from the date of the ILRI Management Committee 
/ Board meeting. 
19.1.7 Any proposed amendment to an SOP or SOPs that is/are not adopted by the 
IREC shall not be effected. 
19.1.8 When new or revised section or sections are approved, the IREC Secretariat 





Appendix A: Glossary 
 
Approval 
The research ethics committee’s affirmation that the clinical trial has been reviewed and 
may be conducted at the nominated institution according to the constraints set out by 
the ethics committee, the institution, and legal requirements. 
Assent  
Permission given to participate in a research study where the individual is not able to 
legally consent. Such individuals can include children and persons with diminished 
cognitive capacity. Assent is obtained from the individual (where possible) and consent is 
obtained from an individual who is legally able to do so. 
Autonomy 
Respecting the decision-making capacities of autonomous persons; enabling individuals 
to make reasoned informed choices 
Beneficence 
This considers the balancing of benefits of research against the risks and costs; the 
researcher professional should act in a way that benefits the research participant, their 
community and or the public generally. 
Benefit 
Something that promotes the wellbeing of an individual or group, or the public generally. 
A benefit for an individual may include access to medications, or access to education 
materials that are known to improve learning. Payment for participation in a study is not 





Pertains to the treatment of information that an individual has disclosed in a relationship 
of trust and with the expectation that it will not be divulged to others without 
permission in ways that are inconsistent with the understanding of the original 
disclosure 
Consent 
The voluntary agreement of a person or group, based on adequate knowledge and 
understanding of relevant material, to participate in research. Informed consent is one 
possible result of informed choice, the other possibility is refusal. Oral consent may be 
used for persons who cannot read or feel uncomfortable signing forms for cultural 
reasons. In this case, a written text describing what will be told to subjects when oral 
consent is necessary should be provided. 
Deception 
Deception includes the withholding of information from research participants, 
deliberately misleading them about procedures and purposes, including studies in which 
participants are deliberately given misleading information about the purpose of a 
research study. When deception is justified in a research study, a researcher must either 
inform the participant of deception in the informed consent, or provide a debriefing 
period and post-debrief consent form following subject participation. 
Harm 
That which adversely affects the interest or welfare of an individual or a group or the 
public generally; harm extends to physical harm, discomfort, anxiety, pain, psychological 
disturbance and includes placing a person at social disadvantage. 
Human subject 
A patient or healthy individual participating in a research study. A living individual about 





This concept concerning fairness or equity is often divided into three parts. Procedural 
justice is concerned with the fair methods of making decisions and settling disputes; 
distributive justice seeks to ensure fair distribution of benefits and burdens, while 
corrective justice is concerned with correcting the wrongs and harms through 
compensation or retribution. 
Minimal risk 
This anticipates that the probability and magnitude of harm or discomfort to be 
experienced in the research will not be greater than those ordinarily encountered in 
daily life. 
Non- maleficence 
Avoiding the causation of harm; the researcher should not harm the research subject. 
Where treatment involves some harm, even if minimal, but the harm should not be 
disproportionate to the benefits of treatment. 
Protocol 
A document that provides the background, rationale, and objective(s) of a biomedical 
research project and describes its design, methodology, and organization, including 
ethical and statistical considerations. Some of these considerations may be provided in 
other documents referred to in the protocol. 
Vulnerable Participants 
Individuals whose willingness to volunteer may be unduly influenced by the expectation, 
whether justified or not, of benefits associated with participation, or of a retaliatory 
response from senior members of a hierarchy in case of refusal to participate. Examples 
are members of a group with a hierarchical structure, such as medical, pharmacy, dental, 
and nursing students. Other vulnerable participants include patients with incurable 
diseases, persons in nursing homes, unemployed or impoverished persons, patients in 
emergency situations, ethnic minority groups, homeless persons, nomads, refugees, 










ILRI maintains an Institutional Research Ethics Committee (IREC) to ensure international 
best practices are met in research involving human subjects. The IREC has the mandate 
to safeguard the dignity, rights, safety and well-being of all actual and potential 
participants in ILRI research and the wider community. All ILRI projects involving 
humans as research subjects, must apply for, and receive, IREC approval before 
commencement of the activities.  
 
This Confidentiality Agreement is intended to protect disclosure of confidential matters 
contained in Research Applications submitted to the IREC for review, including 
Intellectual Property and any other confidential information provided by the application 
to IREC.  “Confidential Subject Matter” shall mean any and all information, know-how 
and data, technical or non-technical, disclosed or provided by Applicant to the IREC 
Committee, whether disclosed or provided in oral, written, graphic, photographic, 
electronic or any other form.     
 
The IREC member and or reviewer agrees to hold in confidence all Confidential Subject 
Matter; not to disclose any Confidential Subject Matter to any third party; and to use 
Confidential Subject Matter solely for the review process. All Confidential Subject 
Matter remains the property of the Applicant.  IREC members are therefore obligated 
to exercise their best judgement in respecting the confidentiality of all applications 
received by the Committee for review. 
 
This Confidentiality Statement remains binding to the IREC Member and or reviewer for 
as long as the Confidential Subject Matter is confidential unless otherwise specified in 









Appendix C: Samples of Consent Form 
Sample 1 
FIELD WORKERS GUIDE – HH survey  
 
Study sites 
We’ll target all 12 in Phnom Penh but excluding those with low/very high density (according to 
last DHS survey). Within target Districts, ILRI will generate 200 random points where the 
households will be identified. Enumerator to walk to the point (using map in tablet) and select 
the first household nearest the point as per below instructions. Number of households for the 
survey = 200. 
 
Identification of households 
Definition of Household: a group of people, most likely from the same family, sharing meals 
and eating at least one main meal for at least 4 days per week. Housemaids, although 
they may be eating at least one main meal in the house for >4days per week are excluded are 
unlikely to be sharing meals with the household.  
 
For each point generated, we will take the closest household to the right, with the team facing 
North. If the next to the right is a multiple storey building, choose RANDOMLY one floor, and 
within that floor, one door to start. Move always to the door on your right (when facing the 
doors), and after going through an entire floor, go to the next up, and when finished, to the next 
down. Introduce yourself and give a brief introduction to the project.  
Introduction: “Good morning. Our names are ___/____ and we come from CelAgrid 
(DESCRIPTION) and the ILRI (The International Livestock Research Institute), an organization 
which does research with livestock and humans. We are working on a project concerned with 
pork consumption and risk of getting sick in Phnom Penh. Over the next few weeks, our team 
will be conducting interviews to households in Phnom Penh and will ask families randomly 
selected about their household pork handling, cooking and consumption practices. You house 
has been randomly selected to participate and we’d like to know if you’d be interested to be 
part of the study. If yes, we will need a maximum 1 hour of your time, or the person in charge 
of food preparation for the family, to answer some questions from us. 
 
If the person agrees to participate, please go through the informed consent process. If not 
agreeable, thank the person and move to the next household as per instructions above.  
 
If they want to participate, but are not available on that moment, make an arrangement for an 
interview at the date/time of convenience. Take their phone number and location and date/time. 
One day before the appointment, call them to confirm time and location.  
 
Best times to find people at home are likely to be before 9am, or after 11 am. We suspect that 
many people will be more available for the interview after 2pm (after lunch time). 
 
Identification of individual to interview 
Ask the person in the household to tell you who in the house is in charge of handling and 
preparing food for the household. That is the person to interview. Ask if that person is also in 
charge of the food purchase from the market. If not the same person, identify the person that 




Informed consent (see last page) – from is being translated to local language (Khmer) 
Notes on sample size 
Given the exploratory nature of this study, we will target 200 households. This number if not 
based on any power calculations, but responds to budget and time constraints. The study is of 
exploratory nature, and aims at generating pilot data.  
 
Protection of privacy and confidentiality 
Participants will be explained the voluntary nature of their participation and that they can decline 
answering any questions they want. The consent forms (hard copies that will include the 
participants name and the survey household ID number) will be kept separately from the data 
(which will be available exclusively in electronic form). The electronic database will contain the 
name of the participant, as well as the GPS coordinates where the house leaves. The name is 
collected to be able to identify the interviewee within the household roster. All names will be 
deleted from the electronic database when the database is shared with individuals/organizations 
outside the research team. The data will be made publicly available in ILRI data portal and/or the 
USAID open data repository.  
Benefits and risks for participants 
We don’t foresee any risks from participation in the study, beyond the time that will take to 
administer the questionnaire. Participants will be given the opportunity to propose a date/time 
of their convenience for the interview. We are also not collecting sensitive data.  
Participants will not receive feedback on the results of the study as this is unlikely to be of direct 
benefit to them. They, however, will be provided with the name and contact details of the team 
leader in Cambodia in case they want to have further information about the study. 
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                    Household ID [                                           ]  
  
Informed consent [please leave a copy of this form with the participant]  
You are being asked to participate in a research study. The study is led by the International 
Livestock Research Institute (which is based in Africa), in collaboration with the Center for 
livestock and Agriculture development (CelAgrid), agricultural development organization based 
in Cambodia. I will now give you a brief explanation of what participating in the study involves so 
that you can decide if you want to participate.   
This research project is trying to obtain information on food consumption and food preparation 
practices in Phnom  
Penh, especially on products of animal origin, to understand the potential food related health 
risks that consumers in Phnom Penh may be exposed to. We will be interviewing 200 
households in Phnom Penh that have been randomly selected. If you agree to participate, we will 
ask you to answer a few questions about our household, the food preparation and consumption 
practices in the house and diarrhea and vomit episodes in the past weeks. This interview will 
take between 45 minutes and 1 hour.   
Participation in this study is entirely voluntary. If you decide to take part, you can choose not to 
answer any of the questions, or change your mind later on and withdraw from the research 
study by phoning the team supervisor (telephone number below). In that case your data will not be 
used. There are no foreseeable risks associated with this study but if you feel uncomfortable, 
you can end the interviews at any time. The research team promises to respect your privacy and 
confidentiality. We will not tell anyone that you participated in this interview and a study 
number rather than your name will be used on study records. Your name will be deleted from 
all the documents that contain data, so that no one can link the data to your name.    
We will not compensate you for your time and participation. We would not be able to come 
back to show you the results of our study. However, we hope the information we will obtain 
from participants in this area will help us understand food safety risks, and support the 
government in developing food safety policies for Phnom Penh and Cambodia in general.   
Do you have any questions?  
I, the person interviewing the participant, confirm that he/she has given him/her consent to 
participate in this study according to the information that has just been given to him/her.  
Consent:  YES  NO Name of participant: ____________________ Signature of 
interviewer:     
‹ I AGREE - Later this year we will be contacting some of the participants in this survey to 
invite them to participate in a nutrition survey (collecting more detailed information on 
food consumption practices). Please indicate if you would agree to be contacted for 




‹ I AGREE - Also, we will invite few participants to some group discussion to get further 
details on food safety and food consumption in Phnom Penh. Indicate if you would agree 
to be contacted for this study.   
Tel. number (if agrees to be contacted again) ___________________  
If you have any further questions or have any concerns about the study, please contact:  
























Animal owner at livestock market consent form 
 
Project name:  
Current research:  
Collaborating Institutions: 
Invitation to participate and description of project 
You are invited to participate in a research study that is designed to develop an integrated 
surveillance system for zoonoses in livestock and humans in western Kenya. Zoonoses are those 
diseases that can be transmitted between animals, including livestock, and humans. We therefore 
plan on sampling cattle, sheep, goats and pigs at selected livestock markets and slaughterhouses 
in Bungoma, Busia and Kakamega Counties. At the same time, we shall also take samples from 
human patients at selected hospitals in the same area. All the samples will be tested for the 
presence of fifteen zoonoses which we know to be present in western Kenya. Through this 
work we will better understand how common these diseases are, and whether they are more 
likely to occur at certain times of the year or in certain places. This information will then help us 
make better recommendations on disease control and prevention strategies.  
In order to decide whether or not you would like to participate we would first like to tell you 
what your participation will involve, and the possible risks and benefits of participating. We 
would like to stress that your participation is entirely voluntary. This work is being carried out 
by independent research workers at ILRI, and our partner institutions. We do not represent any 
government body. 
Description of study procedures 
If you decide to participate, the following things will happen: 
1. Examination and sampling of selected livestock 
The selected livestock (cattle, sheep or goat) will be examined and sampled. We will first 
perform a quick clinical examination of the animal. We will then take either a stool sample or a 
swab from the rectum, and a swab from the nose. We will also take a blood sample, milk 
sample, and hair/fleece clippings. We will also take photographs of any movement permits or 
other relevant documents. At the end we will mark the animal with non-toxic paint markers to 
make sure we do not re-sample it again. 
2. Short questionnaire for the animal’s owner 
a. We will ask you some questions about yourself, including your name, work and 
contact information, and your relation to the animal (e.g. farmer, livestock 
trader, or butcher). 
b. We will then ask you some questions about the selected animal, including: 
i. The age and origin of the animal 
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ii. The reason for buying or selling the animal 
iii. Whether the animal has ever been treated or vaccinated 
iv. Whether the animal has ever been sick or had any abortions 
c. Lastly, we will ask you some questions about any other livestock animals you 
may keep on your household. 
This questionnaire should last 20-30 minutes. 
Confidentiality 
Any personal data disclosed during this interview will remain confidential to the research team, 
and will only be used for the purposes of this project. Your identity will remain anonymous 
throughout. Although we will collect your personal details, these are solely for the purpose of 
contacting you, and will be kept separate from any answers you give to the questionnaire. 
Personal identifying information, such as your name and telephone number, will be securely kept 
and destroyed once the data collection has finished.  
We will record your answers to the questionnaire electronically using a phone or tablet. This 
will be transmitted securely over the internet to computers at ILRI. Your answers and medical 
details will be given codes so that you cannot be identified from our database. All data is kept 
securely, and only the research team will have access to the database. We will not disclose any 
of your information unless we are legally required to do so; for example, in the case that we 
identify a reportable disease, we are obliged to notify the Kenyan authorities. 
All samples taken from the animal will be tested at the field lab in Busia (International Livestock 
Research Institute/Department of Veterinary Sciences Zoonosis Lab) for fifteen different 
zoonotic diseases. We will also store the samples at the laboratory for further research after 
the initial tests are completed. Some of these samples may be sent to international laboratories 
at a later date for further testing, and some may be used to screen for other infections. You will 
not be able to be identified from the samples that you provide, and we will only use them to 
look for infectious diseases. Research results from your individual sample will not be returned to 
you. 
After the project is completed, anonymous samples may be kept in a long-term storage facility at 
ILRI or elsewhere and used for further research. As the storage will be anonymous, you will not 
be personally identifiable, and it will not be possible to report back to you the results of any 
future studies.  
Risks 
Examination and sampling of your animals will be carried out by trained animal health or 
veterinary professionals. The risk to your animals from sampling is very low. Occasionally blood 
sampling may cause some bleeding, swelling or bruising where the blood is collected. Faecal 
sampling or swabbing is normally very safe, except in very rare circumstances if the animal reacts 
and moves violently during the sampling. If you have any concerns about your animals after 





The animal clinical examination and sampling will be provided at no cost to you. If any problems 
are identified during the examination, advice will be provided. 
You will not directly benefit from the research, but we will organize meetings throughout the 
course of the study to communicate some of the results and discuss the research. Government 
departments will also be informed of the research results, and we hope that this will help them 
to make better decisions that bring benefits to both livestock and human populations in western 
Kenya. 
Participation and withdrawal 
We would like to emphasise that your participation is voluntary. If you consent and then later 
decide that you would like to withdraw, you are free to do this at any point.  
If you later decide that you do not want that the samples taken from your animal, or your 
information, to be used in the study, you can contact the study team and ask that your 
contribution be withdrawn. Contact details are provided below. 
If there is anything that you have not understood, please feel free to ask questions. You are 
welcome to ask us to go over any aspect of this form again before you decide whether or not to 
participate. 
Authorisation 
I confirm that I have read (or someone has read to me) this form, and I have understood the 
purposes of the research, what my participation will involve and any risks of the research. I 
agree to participate in the project described. 
 
Name of animal owner…………………………………………………………………………. 
 




Signature of Investigator……………………………………………………………………… 
Contact details:  
If you have any further questions about this project, or you have a research-related problem, 
please contact a member of the study team.  




Investigator contact number ………………………………………………………………. 
Project Manager:   Tel:  
Project Researcher:   Tel:  
Principal Investigator:  Tel:  
If you have any concerns about the way that the research has been conducted and would like to 
speak to an independent member of the Institutional Research Ethics Committee, please 
contact:  
 
ILRI IREC Secretariat 
ILRI, Old Naivasha Road, PO Box 30709-00100, Nairobi  





















Human patient consent form 
Project name:  
Current research:  
Collaborating Institutions: 
Invitation to participate and description of project 
You are invited to participate in a research study that is designed to develop an integrated 
surveillance system for zoonoses in livestock and humans in western Kenya. Zoonoses are those 
diseases that can be transmitted between animals, including livestock, and humans. We therefore 
plan on sampling cattle, sheep, goats and pigs at selected livestock markets and slaughterhouses 
in Bungoma, Busia and Kakamega Counties. At the same time, we shall also take samples from 
human patients at selected hospitals in the same area. All the samples will be tested for the 
presence of fifteen zoonoses which we know to be present in western Kenya. Through this 
work we will better understand how common these diseases are, and whether they are more 
likely to occur at certain times of the year or in certain places. This information will then help us 
make better recommendations on disease control and prevention strategies.  
In order to decide whether or not you would like to participate we would first like to tell you 
what your participation will involve, and the possible risks and benefits of participating. We 
would like to stress that your participation is entirely voluntary. This work is being carried out 
by independent research workers at ILRI, and our partner institutions. We do not represent any 
government body. 
 
Description of study procedures 
If you decide to participate, the following things will happen: 
Short questionnaire, health screen and sampling  
a. We will ask you some questions about yourself, including your name, age, family 
status, work and contact information. We will also ask you about your eating 
habits. If you come into contact with animals either at work or at home, we will 
also ask you about this. 
b. We will then ask you the reason for visiting the hospital, whether anyone else in 
your family is also suffering from the same symptoms, and whether you have 
taken any medicines in the last six months. We will also ask you about any 
vaccinations you may have taken.  
c. We will perform a general clinical examination and health check, recording your 
weight, height, pulse, blood pressure and temperature. 
d. We will take a swab from inside your nose 
e. We will ask you to provide a stool sample. In the event that you cannot provide 
a sample, we may ask permission to take a swab from your rectum instead. 
f. We will take a blood sample. 
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g. We may ask you for a sputum sample 
This should last 20-30 minutes. 
 
Confidentiality 
Any personal data disclosed during this interview will remain confidential to the research team, 
and will only be used for the purposes of this project. Your identity will remain anonymous 
throughout. Although we will collect your personal details, these are solely for the purpose of 
contacting you, and will be kept separate from any answers you give to the questionnaire. 
Personal identifying information, such as your name and telephone number will be securely kept 
and destroyed once the data collection has finished.  
We will record your answers to the questionnaire electronically using a phone or tablet. This 
will be transmitted securely over the internet to computers at ILRI. Your answers and medical 
details will be given codes so that you cannot be identified from our database. All data is kept 
securely, and only the research team will have access to the database. We will not disclose any 
of your information unless we are legally required to do so; for example in the case that we 
identify a reportable disease, we are obliged to notify the Kenyan authorities. 
All samples that you provide will be tested at the field lab in Busia (International Livestock 
Research Institute/Department of Veterinary Sciences Zoonosis Lab) for fifteen different 
zoonotic diseases. We will also store your samples at the laboratory for further research after 
the initial tests are completed. Some of these samples may be sent to international laboratories 
at a later date for further testing, and some may be used to screen for other infections. You will 
not be able to be identified from the samples that you provide, and we will only use them to 
look for infectious diseases. Research results from your individual sample will not be returned to 
you. 
After the project is completed, anonymous samples may be kept in a long-term storage facility at 
ILRI or elsewhere and used for further research. As the storage will be anonymous, you will not 
be personally identifiable, and it will not be possible to report back to you the results of any 
future studies.  
Risks 
All health checks will be carried out by trained medical staff. There are no risks involved with 
the health examination, the nasal swab, blood sampling, or with providing a stool sample. If you 
cannot provide a sample, then we may instead request permission to take a sample by anal 
swabbing, which may cause you a short period of discomfort. You may become tired during the 
examination. If you experience any problems during the study, please alert the research team, 
who will allow you to take a break. You are also free to withdraw from the study at any time. 
Benefits 
The general health screen will be provided at no cost to you. If any problems are identified 
during the examination, advice will be provided. 
Although in general we will not report research results back to you individually, in the event 
that we identify a reportable disease, we will undertake to inform your clinicians at the hospital. 
You will not directly benefit from the research, but we will hold a community meeting to discuss 
the research at a later date. Government departments will also be informed of the research 
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results, and we hope that this will help them to make better decisions that bring benefits to both 
livestock and human populations in western Kenya. 
Participation and withdrawal 
We would like to emphasise that your participation is voluntary. If you consent and then later 
decide that you would like to withdraw, you are free to do this at any point.  
If you later decide that you do not want that the samples taken from you, or your information, 
to be used in the study, you can contact the study team and ask that your contribution be 
withdrawn. Contact details are provided below. 
If there is anything that you have not understood, please feel free to ask questions. You are 
welcome to ask us to go over any aspect of this form again before you decide whether or not to 
participate. You are also welcome to ask about other aspects of the study overall. 
Authorisation 
I confirm that I have read (or someone has read to me) this form, and I have understood the 
purposes of the research, what my participation will involve, and any risks of the research. I 
agree to participate in the project described. 
Name of human patient………………………………………………………………………… 
Signature / thumb print…………..…………………………………………………………… 
Date……………………………………………………………………………………………… 
 
Signature of Investigator……………………………………………………………………… 
 
Contact details:  
If you have any further questions about this project, or you have a research-related problem, 
please contact a member of the study team.  
 
Investigator name …..………………………………………………………………………… 
 
Investigator contact number …………………………………………………………………. 
Project Manager:   Tel:  
Project Researcher:   Tel:  
Principal Investigator:  Tel:  
 
If you have any concerns about the way that the research has been conducted and would like to 





ILRI IREC Secretariat 
ILRI, Old Naivasha Road, PO Box 30709-00100, Nairobi  




























Project Title:  
Introduction for community conversations– seeking consent 
Key objectives of an introduction: 
- Explain why you are doing the community conversations.  
- Explain what you would like to do and how long it might take. 
- Explain about confidentiality. 
- Ask if there are any questions before starting. 
- Ask the participants to introduce themselves. 
Suggested script: 
Thank you for coming. My name is ____________________, and I work for 
_____________. I am with a team of researchers from (mention the institutions). We are 
conducting a study to understand (i) your knowledge about diseases that are transmitted from 
animals to humans (ii) the role of men, women, and children in managing these diseases (iii) how 
livestock resources are managed, and (iv) develop a plan of action to manage these diseases and 
how men and women manage household and community resources. We shall be discussing 
issues about your experiences with diseases transmitted from animals to humans, the roles of 
household members in managing livestock, ownership of livestock, and the rules, regulations, 
norms regarding management of livestock and their diseases. These issues will be discussed in 
four separate sessions. 
The information you give us will be completely confidential. We will describe what people in this 
community and others think in a report, but we will not mention any names. Your personal 
contributions and views will not be shared with anyone else in a way that can identify you. 
Also, you don’t have to participate if you don’t want to, and please interrupt me if you ever 
want to stop the conversion. The discussion will take about four hours. Your views will be 
treated with utmost confidentiality. 




INDIVIDUAL INTERVIEW - CONSENT 
Thank you very much. My name is ____________________, and I work for_____.  This 
institution works in collaboration with ________to address issues related to livestock 
production and improve livelihoods of small holder farmers. We are conducting a study to 
understand (i) your current knowledge about diseases that are transmitted from animals to 
humans and (ii) the current animal and disease management practices you use at home. We shall 
be discussing issues about your experiences with diseases, the roles of household members in 
managing livestock, ownership of livestock, and your perceptions about different livestock 
management practices. You have been selected because you keep livestock, particularly small 
ruminants and you have the knowledge about animal production and diseases. In future, we shall 
visit you again to collect the same information to determine if any change has happened. 
The information you give us will be completely confidential. We will describe what people in this 
community and others think in a report, but we will not mention any names. Your personal 
contributions and views will not be shared with anyone else in a way that can identify you. 
Also, you don’t have to participate if you don’t want to, and please interrupt me if you ever 
want to stop the discussion. The discussion will take about 30 minutes. Your views will be 
treated with utmost confidentiality. 
Do you have any questions before we proceed?  
Do you agree to participate in this study? 1. Yes   2. No 
If yes, we can begin. 
Thank you very much.  
ILRI IREC Secretariat 
ILRI, Old Naivasha Road, PO Box 30709-00100, Nairobi  












Individual consent form – Value Chain 
Project name:  
Current research:  
Collaborating Institutions: 
Invitation to participate and description of project 
You are invited to participate in a research study that is designed to look at how certain types of 
bacteria move around Nairobi. We are studying a number of bacteria, including E. coli and 
Campylobacter, that can cause diarrhoea in people, especially children. However, a lot of these 
bacteria can also live quite harmlessly, without causing any problems, in people, in animals, and 
in food and water. Our research is trying to find out what makes some of these bacteria more 
likely to cause health problems, and whether there are certain things about the way different 
people live in Nairobi that makes them more at risk of getting infected with these bacteria. 
In order to decide whether or not you would like to participate we would first like to tell you 
what your participation will involve, and the possible risks and benefits of participating. We 
would like to stress that your participation is entirely voluntary. This work is being carried out 
by independent research workers at ILRI, and our partner institutions. We do not represent any 
government body. 
Description of study procedures 
The full study that your employer has agreed to take part in involves sampling different parts of 
the premises for the bacteria of interest, including the animals and/or meat. In addition, we will 
be trapping and sampling wildlife from around the premises. Your employer already has a copy 
of the form that you can look at if you have any further questions on any of these aspects. 
This consent form is for you as an individual, and relates to your personal participation in the 
study. Even if your employer has consented to be part of this study overall, we would like to 
stress that your participation as an individual is entirely voluntary.  
If you decide to participate, the following things will happen: 
1. We will ask you some questions about yourself, including your age, education, work, 
eating habits and any recent health problems.  
2. We will perform a general health check, including weight, height, arm size and 
temperature 
3. We will take a swab from inside your nose 
4. We will ask you provide a stool sample.  
 
Confidentiality 
Any personal data will remain confidential to the research team, and will only be used for the 
purposes of this project. Your identity will remain anonymous throughout. Although we will 
collect your personal details, these are solely for the purpose of contacting you, and will be kept 
separate from your questionnaire answers and your medical details. Personal identifying 
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information, such as your name and telephone number will be securely kept and destroyed once 
the data collection has finished.  
We will record your answers electronically using a tablet, and transmit them securely over the 
internet to computers at ILRI. Your answers will be given a barcode so that you cannot be 
identified from our database. All data is kept securely, and only the research team will have 
access to the database. We will not disclose any of your information unless we are legally 
required to do so; for example in the case that we identify a reportable disease, we are obliged 
to notify the Kenyan authorities. 
All samples that you provide, along with the samples from your workplace, will be tested by our 
laboratories at the University of Nairobi and the Kenya Medical Research Institute for bacteria. 
Any bacteria grown may be sent to international laboratories at a later date for further testing. 
You will not be able to be identified from the samples that you provide, and we will only use 
them to look for infectious diseases. Results from your individual sample will not be returned to 
you or your doctor. 
After the project is completed, anonymous samples may be kept in a long-term storage facility at 
ILRI or elsewhere and used for further research. As the storage will be anonymous, you will not 
be personally identifiable, and it will not be possible to report back to you the results of any 
future studies.  
Risks 
All health checks will be carried out by trained medical staff. There are no risks involved with 
the health examination, the nasal swab, or with providing a stool sample. You may become tired 
during the examination. If you experience any problems during the study, please alert the 
research team, who will allow you to take a break. You are also free to withdraw from the 
study at any time. 
Benefits 
The general health screen will be provided at no cost to you. If any problems are identified, 
advice will be provided, and you will be referred to a medical facility if necessary for further 
treatment. 
Although in general we will not report research results back to you individually, in the event 
that you are currently suffering from diarrhoea and we identify particular bacteria 
(Campylobacter) in your faecal sample, we will inform you, as this organism may require 
treatment. The other bacteria we are researching are present in healthy people, and therefore 
not normally relevant to your personal health. 
You will not directly benefit from the research, but we will report overall (not individual) results 
to the management at a later date. This may help them to develop management strategies to 
improve meat hygiene and worker safety. Government departments will also be informed of the 
research results, and we hope that this will help them to make better decisions that bring 
benefits to the communities for health, housing and livestock keeping in Nairobi. 
Participation and withdrawal 
We would like to emphasise that your participation is voluntary. Even though your employer has 
consented to be part of the overall study, you are free to decline to take part as an individual. If 
you consent and then later decide that you would like to withdraw, you are free to do this at 
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any point. We will not tell your employer if you decide that you do not want to be part of this 
study. If you do not want your employer to know of your decision, you may ask the researcher 
to read out the questionnaire and answer “decline” to each question, so your employer may not 
guess that you do not want to take part. You may, if you choose, still receive the health check, 
even if you decline to answer the questionnaire.  
If you later decide that you do not want your samples or your information to be used in the 
study, you can contact the study team and ask that your contribution be withdrawn. Contact 
details are provided below. 
 
Participation of ………………………………………………… (enter employer’s name) 
(hereby referred to as “your employer”) 
Although we are collaborating with your employer with regard to this project, we confirm that 
the relationship between you and ILRI is strictly confidential and no personal results that come 
from the tests conducted following your voluntary agreement to participate in the study will be 
disclosed by us to your employer. Your employer will not be held responsible or liable in any 
way at all should a particular problem be identified and you be informed of the same as provided 
under Paragraph 2 of Benefits above.  
If there is anything that you have not understood, please feel free to ask questions. You are 
welcome to ask us to go over any aspect of this form again before you decide whether or not to 
participate. You are also welcome to ask about other aspects of the study overall. 
Authorisation 
I confirm that I have read (or someone has read to me) this form, and I have understood the 
purposes of the research, what my individual participation will involve and any risks of the 
research. I agree to participate in the project described. 
I further confirm and understand that my employer 
……………………………………………………………………. will not be party to any 
individual results of any samples taken from me as a consenting individual, and that I will not be 
able to hold my employer responsible or liable in any way should the samples identify any 
problem that I may have as outlined under Benefits above. 
I further confirm and understand that the overall results of the study, but not individual results, 
will be released to my employer as part of their collaboration with ILRI in this study, and that 
these results will not necessarily be shared with participating individuals. 
Name of individual………………………………………………………………………………. 
 








If you have any further questions about this project, or you have a research-related problem, 
please contact a member of the study team.  
 
Investigator name …..………………………………………………………………………… 
 
Investigator contact number …………………………………………………………………. 
Field co-ordinator:   Tel:  
Project Researcher:   Tel:  
Principal Investigator:   Tel:  
 
If you have any concerns about the way that the research has been conducted and would like to 
speak to an independent member of the Institutional Research Ethics Committee, please 
contact:  
 
ILRI IREC Secretariat 
ILRI, Old Naivasha Road, PO Box 30709-00100, Nairobi  
 

















Subject information sheet and Informed consent form 
 
Subject information sheet 
 
This sheet is to be read for the participants of the study before collecting any 
information from them. 
 
Hello. My name is ______________I am here on behalf of _________________, 
student of ______________________________, College of Health Sciences and 
School of Public Health. She is conducting a research on ‘Aflatoxin exposure level and its 
association with stunting in young children’ in _______________, for the partial 
fulfilment of master’s in public health. She received permission from 
_______________________, School of public health and 
________________________ regional health bureau to conduct this study. You are 
selected by chance to participate in this study, because you are a mother/care giver of a 
child 1-4 years old. You will participate if you give me consent after you have 
understood the following information: 
 
What the study is about: The purpose of the study is to know whether young 
children in Ethiopia are exposed to Aflatoxin and if this exposure is related with 
stunting. Aflatoxins are naturally occurring toxic by-products that contaminate staple 
foods and cause different health consequences on humans and animals. Evidences 
suggest several mechanisms by which aflatoxin can impair growth and development in 
children. 
 
Design of the study: The study is a cross-sectional study among children age 1-4 
years. 
 
What I will ask you to do: If you agree to participate in this study, I will conduct an 
interview that will take about 20-30 minutes. Your child’s height will be measured and I 
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will collect 20mlof morning urine sample from your child. I would very much appreciate 
your participation in this study. 
 
Risks and Benefits: The result of the study helps to develop strategies and 
interventions targeting children in order to reduce aflatoxin exposure and to prevent 
the health consequences following it. In this way your child may benefit from the 
intervention policy. There is no payment and risk you should fear as a result of 
participating in this study. 
 
Confidentiality: All information given by you will be kept confidential. Any of yours 
and your child’s personal information will not register. The records of the study will be 
kept private, only the researchers will have access to the records. Your child name will 
not be included in the urine sample taken, which will protect his/her identity and 
preserve anonymity. In any sort of report, we make public we will not include any 
information that will make it possible to identify you. 
 
Taking part is voluntary: Your participation is purely based on your willingness. You 
have the right to choose not to take part in the study. If you choose to take part, you 
have the right to stop at any time. If you are willing to participate or refuse or decide to 
withdraw later, you will not be subjected to any ill-treatment. 
 
If you have questions: If you have questions regarding this study, you can contact the 
principal investigator and if you need to clarify the question, you can ask me at any time 
of the interview. 






Are you willing to participate in this study? 
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1. Yes (take informed consent and continue the interview) 
2. No (write the reason for refusal and continue with the next participant) 
___________ 
I, the selected participant of the study has understood the information sheet and I am 
willing to participate in this study. 
 
Informed consent certified by: 
Respondent’s signature___________ Date___________ 
Data collector: Name______________ Signature__________ 
The date of data collection Time started_______ End time________ 
 
ILRI IREC Secretariat 
ILRI, Old Naivasha Road, PO Box 30709-00100, Nairobi  


















Sample 7: Assent Form 
Assent form for human patients under 18 
 
Project name:  
Current research:  
Collaborating Institutions:  
Invitation to participate and description of project 
You are invited to participate in a research study that is designed to develop an integrated 
surveillance system for zoonoses in livestock and humans in western Kenya. Zoonoses are those 
diseases that can be transmitted between animals, including livestock, and humans. We therefore 
plan on sampling cattle, sheep, goats and pigs at selected livestock markets and slaughterhouses 
in Bungoma, Busia and Kakamega Counties. At the same time, we shall also take samples from 
human patients at selected hospitals in the same area. All the samples will be tested for the 
presence of fifteen zoonoses which we know to be present in western Kenya. Through this 
work we will better understand how common these diseases are, and whether they are more 
likely to occur at certain times of the year or in certain places. This information will then help us 
make better recommendations on disease control and prevention strategies.  
In order to decide whether or not you would like to participate we would first like to tell you 
what your participation will involve, and the possible risks and benefits of participating. We 
would like to stress that your participation is entirely voluntary. This work is being carried out 
by independent research workers at ILRI, and our partner institutions. We do not represent any 
government body. 
Description of study procedures 
If you decide to participate, the following things will happen: 
If you are between the age of 5 and 18: 
Short questionnaire, health screen and sampling  
h. We will ask you some questions about yourself, including your name, age, family 
status, any work you do, and contact information. We will ask you about your 
eating habits. If you come into contact with animals either at work or at home, 
we will also ask you about this. 
i. We will then ask you the reason for visiting the hospital, whether anyone else in 
your family is suffering from the same symptoms, and whether you have taken 
any medicines in the last six months. We will also ask you about any 
vaccinations you may have taken.  
j. We will perform a general clinical examination and health check, recording your 
weight, height, pulse, blood pressure and temperature. 
k. We will take a swab from inside your nose. 
l. We will ask you provide a stool sample. In the event that you cannot provide a 
sample, we may ask permission to take a swab from your rectum instead. 
m. We will take a blood sample. 
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n. We may ask you for a sputum sample. 
For children under 5 years: 
Health screen, short questionnaire and stool sample  
a. Parents will be asked a short questionnaire on their child’s eating habits and 
possible contact with animals. 
b. Parents will be asked the reason for bringing the child to the hospital, whether 
anyone else in the family (including themselves) are suffering from the same 
symptoms, whether the child has taken any medicines in the last six months, and 
whether the child has had any vaccinations.  
c. We will perform a general clinical examination and health check on the child, 
recording weight, height, and temperature. 
d. We will take a swab from inside the child’s nose 
e. We will ask for the child to provide a stool sample. In the event that they 
cannot provide a sample, we may ask permission to take a swab from their 
rectum instead. 
f. We will take a blood sample. 
g. We may ask for a sputum sample. 
This should last 20-30 minutes. 
 
Confidentiality 
Any personal data disclosed during this interview will remain confidential to the research team, 
and will only be used for the purposes of this project. Your identity will remain anonymous 
throughout. Although we will collect your personal details, these are solely for the purpose of 
contacting you, and will be kept separate from any answers you give to the questionnaire. 
Personal identifying information, such as your name and telephone number will be securely kept 
and destroyed once the data collection has finished.  
We will record your answers to the questionnaire electronically using a phone or tablet. This 
will be transmitted securely over the internet to computers at ILRI. Your answers and medical 
details will be given codes so that you cannot be identified from our database. All data is kept 
securely, and only the research team will have access to the database. We will not disclose any 
of your information unless we are legally required to do so; for example in the case that we 
identify a reportable disease, we are obliged to notify the Kenyan authorities. 
All samples that you provide will be tested at the field lab in Busia (International Livestock 
Research Institute/Department of Veterinary Sciences Zoonosis Lab) for fifteen different 
zoonotic diseases. We will also store your samples at the laboratory for further research after 
the initial tests are completed. Some of these samples may be sent to international laboratories 
at a later date for further testing, and some may be used to screen for other infections. You will 
not be able to be identified from the samples that you provide, and we will only use them to 
look for infectious diseases. Research results from your individual sample will not be returned to 
you. 
After the project is completed, anonymous samples may be kept in a long-term storage facility at 
ILRI or elsewhere and used for further research. As the storage will be anonymous, you will not 
be personally identifiable, and it will not be possible to report back to you the results of any 





All health checks will be carried out by trained medical staff. There are no risks involved with 
the health examination, the nasal swab, blood sampling, or with providing a stool sample. If you 
cannot provide a sample, then we may instead request permission to take a sample by anal 
swabbing, which may cause you a short period of discomfort. You may become tired during the 
examination. If you experience any problems during the study, please alert the research team, 
who will allow you to take a break. You are also free to withdraw from the study at any time. 
For children under 5, we will confirm that they are comfortable with each part of the 
examination, and we can stop the examination at any point either at the request of the adult 
family member or if the child indicates distress or refuses to continue with the examination. 
Benefits 
The general health screen will be provided at no cost to you. If any problems are identified 
during the examination, advice will be provided. 
Although in general we will not report research results back to you individually, in the event 
that we identify a reportable disease, we will undertake to inform your clinicians at the hospital. 
You will not directly benefit from the research, but we will hold a community meeting to discuss 
the research at a later date. Government departments will also be informed of the research 
results, and we hope that this will help them to make better decisions that bring benefits to both 
livestock and human populations in western Kenya. 
Participation and withdrawal 
We would like to emphasise that your participation is voluntary. If you consent and then later 
decide that you would like to withdraw, you are free to do this at any point. As you are under 
18, both the health check and the questionnaire must be carried out in the presence of an adult 
member of your family. If there are any parts of the questionnaire you do not wish to answer, 
you may say “decline”. Either you or your adult family member can choose to stop the interview 
at any point. Adults answering on behalf of children under 5 may also choose to stop at any 
time. You may still (choose for your child to) receive the health check, even if you decline to 
answer the questionnaire. 
If you later decide that you do not want that the samples taken from you to be used in the 
study, you can contact the study team and ask that your contribution be withdrawn. Contact 
details are provided below. 
If there is anything that you have not understood, please feel free to ask questions. You are 
welcome to ask us to go over any aspect of this form again before you decide whether or not to 
participate. You are also welcome to ask about other aspects of the study overall. 
Authorisation 
Minor’s statement (5-18) 
I confirm that I have understood the above description of the study and that I have had the 
opportunity to ask any questions about this study that I wish to ask. I confirm that I am happy to 
answer the questions that will be asked of me and that I am happy to allow the project team to 
examine me and to take the necessary samples for this project.  
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Name of individual………………………………………………………………………… 
Signature / thumb print…………..………………………………………………………… 
 
Authorisation 
I confirm that I have read (or someone has read to me) this form, and I have understood the 
purposes of the research, what my child’s participation will involve and any risks of the research. 
I confirm that I am happy (for my child) to answer questions and that I am happy for my child to 
be examined and provide the necessary samples as described.  
 
Name of consenting adult……………………………………………………………………… 
 




If you have any further questions about this project, or you have a research-related problem, 
please contact a member of the study team.  
Investigator name …..………………………………………………………………………… 
Investigator contact number ………………………………………………………………… 
Project Manager:   Tel:  
Project Researcher:   Tel:  
Principal Investigator:  Tel:  
If you have any concerns about the way that the research has been conducted and would like to 
speak to an independent member of the Institutional Research Ethics Committee, please 
contact:  
 
ILRI IREC Secretariat 
ILRI, Old Naivasha Road, PO Box 30709-00100, Nairobi  






Appendix D: Research Compliance Form 
 
ILRI Research Compliance Form – Assessment of Compliance 
with Regulations & Standards 
 
Please submit this form to EOHS/Research Compliance Unit  via 
ILRIResearchcompliance@cgiar.org  after completing all sections 
BACKGROUND: 
 The purpose of this form is to ensure that your project complies with ILRI 
guidelines, regulatory requirements and international standards for carrying out 
research. 
 ILRI has established independent research compliance committees i.e. Institutional 
Biosafety Committee (IBC), Institutional Animal Care and Use Committee (IACUC) 
and Institutional Research Ethics Committee (IREC) that evaluates all ILRI research 
projects on biosafety, animal welfare and human ethics respectively. Please visit 
www.ilri.org/researchcompliance for more information. 
 For more information or clarification, please contact EOHS office by sending an 
email to ILRIResearchcompliance@cgiar.org 
 
1. Project Details: 
 
Project title (max. 30 words):  
Project start date:  Project end date:  
Project Donor:  
Project budget code  
(team, location & grant code): 
 
 
2. Principal Investigator(s) 
 
Principal Investigator (PI): 
(incl. Institutional affiliation, address & telephone contact. Include 
Applicant details if different from PI) 
 
Other named investigators on project: 
(incl. Institutional affiliation, address & telephone contact)  
 





Does your project include collection of samples from animals and or plants? If YES, contact 
EOHS for the access and befits sharing (ABS) process. 
 
Does your research involve collection of traditional knowledge associated with a genetic 




Does your project include importation and or exportation of research materials or samples? 
If YES, complete the Movement of Research Materials Form. 
 
 





Does your project include field work? If YES, complete form RA1.2  
Does your project include laboratory-based activities? If YES, complete form RA2.1 and 
indicate name of the lab (ADD/NBI) & room number. 
 
Does your project include working with biological agents? If YES, complete form RA3.1  
Does your project include recombinant DNA work? If YES, complete form RA4.1  
Does your project include the use of retroviral vectors? If YES, complete form RA4.2  
Does your project involve modifying non-exempt prokaryotic and/or eukaryotic cells? If YES, 
complete form RA4.3 
 
 





Does your project include genetically modified animal experiments? If YES, complete Form 
RA5.1 – Risk Assessment for Genetically Modified Animals 
 
Does your project include genetically modified plant experiments? If YES, complete Form 
RA5.2 – Risk Assessment for Genetically Modified Plants  
 









Does your project involve handling, use or collection of invasive data (including any type of 
biological sample) from animals? If YES, complete the IACUC FORM 
 
Does your research involve moving animals from one location to another within Kenya? If 
YES, contact EOHS for animal movement permit. 
 
 





Does your project involve collecting information and or human biological samples on and/or 
from humans? If YES, complete the IREC FORM 
 
Has the project proposal been approved by another IREC or IRB? If YES, attach letter of 
approval. 
 
Does the project inviolve taking of photographs not as part of research data collection? If 
YES, refer to ILRI guidelines on taking photographs. 
 
Has your project been submitted to another IREC or IRB for ethics review? If YES, please  
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give the name of the IREC or IRB. 
 
8. Assurances  
I agree to abide by all rules and regulations as determined by the above risk and ethics asessment of the 
proposed research. 
 
Prior to undertaking this research, all personnel will receive appropriate instruction to ensure 
compliance with both local and international guidelines. 
 
I agree to send a revised project description if changes made to protocols may alter the status of any of 
the above responses. 
Signature of Principal Investigator *:   Date:   







Appendix E: IREC Application Form 
 
IREC APPLICATION FORM 
 
This form is to be submitted to ILRIResearchcompliance@cgiar.org along with any 
relevant documentation after completing all sections and all endorsements (see Annex 
for instructions). 
POINTS TO NOTE: 
 This form is valid, unchanged, for one year.  
 If minor changes are required then the IREC MINOR AMENDMENT FORM (see website for 
form - www.ilri.org/ethicscommittee) should be completed and sent to the IREC committee for 
consideration. 
 If renewal of approval is required then the IREC RENEWAL OF APPROVAL FORM (see 
website for form - www.ilri.org/ethicscommittee) should be completed and sent to the IREC 
committee for consideration. 
 The committee requires the form to be submitted to the IREC committee at least 6 weeks before 
the start of the research activity to enable sufficient time for it to be approved. 
 The ILRI IREC committee follows international standards for research ethics and follows the 
principles of research ethics (autonomy, beneficence, non - maleficence and justice).   
 
 
Approval Type Requested: 
X the box which applies. Note that ‘Conditional’ applications should be followed up by ‘Final’ applications at 
project activity planning stage 
Conditional (e.g. project proposal stage)  Final (e.g. project activity planning stage)  
If previous conditional approval received give the IREC ref. number  
Approval for a whole project  Approval for an activity within a project  
If an activity within a project, give the title of the project  
 
1. Title of research project & activity: Overall project title & research activity to which this form refers (Max. 30 words) 
 
 
2. Team, location & grant code under which research activity falls: e.g. BT02 NBO WEL004 
 
 
3. Principal Investigator (PI): 






4. ILRI staff responsible & role:   
5. Names or description of others 









7. Regulatory Requirements / Guidelines:  
Are you in compliance with local regulatory requirements (give details & info. on any 
approvals required) 
  
IREC ref no. 
 




8. Anticipated benefits:  
1. Anticipated benefits to research participants and their community 





9a. Anticipated risks and their 
management 
1. Anticipated risks to research participants 
2. Anticipated risks to personnel involved in conducting the research 
3. Anticipated risks to animals, environmental sustainability, economy or development 






10. Research activity details / 
protocol 
1. Study type / design (incl. use of ‘counterfactuals’, if relevant & site selection)  
2. Justification for number of participants (e.g. power / sample size calc.) 
3. Plans for data management & analysis  





11. Recruitment & involvement 
of research participants and 
informed consent 
1. Means of recruitment (incl. inclusion & exclusion criteria, withdrawal criteria)  
2. Means by which full information about the research activity will be conveyed to communities / participants 





12. Protection of privacy & 
confidentiality 
Detail the following: 
1. Measures taken to ensure privacy (during data collection & after) 





13. Feedback to communities & 
participants 
How will research results be made available to research participants and the communities (detail for each 





14. Proposed (future) commencement 
date: 
 Duration:  
 
9b. Care and protection of 
research participants 
Regarding ‘risks to research participant’ in Section 10, Detail here: 
1. Any medical care or treatments to be provided 
2. Any rewards and compensations for research participants 





15. Details on site facilities, equipment & 
skills of technical staff 
Explain the various technical facilities required / in place for the research (e.g. labs, field stations) 
& the skills and any relevant training required e.g. medical qualifications for human sampling, 






List relevant research instruments attached: e.g. consent form, questionnaire, interview guide, 






17. Other ILRI approvals required?: 
1. Research activities involving animals require an IACUC form (this also covers the Ethical 
issues relating to research on animals) 
2. Research activities involving biohazardous substances must be approved by the IBC 
Required? (X if yes) Reference (if already received) 
Institutional Animal Care & Use Committee (IACUC)   
Institute Biosafety Committee (IBC)   
 
18. Endorsements: 
Main signatures in the order below signify that all necessary obligations/requirements have 
been satisfied. 
Signature of Principal Investigator *:   Date:   
Signature of Program Leader :  Date  
Signature of DDG-R (IS or BioS) :  Date:  
 
* I certify that the any revision to this protocol will be forwarded to the IREC for review using the IREC amendment form and 




IREC USE ONLY 
 
Date received by IREC:  Received by:  
Application number:  
 




Action (what / by whom): 
   
   
   
   
   
IREC FINAL APPROVAL: 








The sign-off procedure is as follows  
 
N.B. This process / chain should be indicated by FORWARDING e-mails through the 
process 
 
Principal Investigator (PI): This is be the person (researcher) who takes responsibility for ensuring 
that the experiment runs as stated in the protocol - and that animals are cared for as they should be. The 
PI should be the person who is touch with the field staff and can answer and explain all questions about 
the way the protocol is implemented and why. They will be based wherever the experiment is taking 
place. 
 
Program Leader: This is the person who is directly responsible for the research project under which 
the PI is working and is likely to be the supervisor of the PI. In some cases PI and program leader will be 
the same person. 
 
Deputy Director General Research - Integrated Sciences / BioSciences: DDG under which the 
Program, project and PI falls. 
 
Approval of Scientific Merit (PL& DDG Approval Required): 
The IREC assumes that the proposed research has been reviewed and approved on the basis 
of scientific merit by the relevant PL & DDG, evidenced by their signed-off or his/her 






Appendix F: IREC Minor Amendment Form 
 
IREC MINOR AMENDMENT FORM  
 
Note 1: A change in Overall Objectives or addition of Research Components are not considered minor changes; in these situations, 
a new IREC NEW APPLICATION should be submitted to IREC for review and approval.  
Note 2: Changes to ‘Commencement Date’ or updated references from other committees may be communicated to the IREC 
Secretariat directly on ILRIResearchcompliance@cgiar.org who will inform the committee and update the IREC NEW 
APPLICATION FORM. 
Note 2: Upon review of this minor amendment form the IREC may request that a new IREC NEW APPLICATION FORM be 
submitted. 
 
Principal Investigator: Program, location & grant code: 
IREC Reference No.:  
 
NATURE OF CHANGE: please check all that apply in grey box and provide details AND reasons for proposed changes. 
Proposed changes must be clearly identified and contrasted with the previously approved IREC NEW APPLICATION FORM. 
 
 Personnel  




Other Regulatory Requirements / 
Guidelines  
 
 Anticipated benefits  
 Anticipated risks & their management  
 
Care & protection of research 
participants 
 
 Research activity details / protocol  
Study design changes (e.g. sites, number of participants): 
 





Recruitment & involvement of research 
participants & informed consent 
Changes in recruitment and/or informed consent process: 
 Protection of privacy & confidentiality 
 
 
 Feedback to communities & participants  
 
Details of site facilities, equipment & skills 
of technical staff 
 
 Change in Instruments used 
Attach updated Instruments to this application & highlight key changes: 
 









Submit the signed form electronically to ILRIResearchcompliance@cgiar.org    
This form and all related IREC forms can be found on the IREC web page: www.ilri.org/ethicscommittee 
 
IREC Use Only 
Comments on minor amendments: 
 
 













Appendix F: IREC Renewal of Approval Form 
 
1  
IREC RENEWAL OF APPROVAL FORM 
 
Note: It is your responsibility as the Principal Investigator (PI) to maintain ethics clearance on your research project and to report when the project is 
completed or terminated. To avoid a lapse in ethics clearance, please ensure that you apply for an extension by completing this form and sending it to 
ILRIResearchcompliance@cgiar.org at least one month before the date of expiry.   
 
Principal Investigator:  
Program, location & grant 
code: 
 
IREC Reference No.:  
Date of Original Approval:  
Renewal Period Requested From:                                                                                     To: 
 
Status of the Study: Provide a summary of your study indicating tasks which have been completed, challenges experienced and lessons learnt so far. If 


















Submit the signed form electronically to ILRIResearchcompliance@cgiar.org    








IREC Use Only 
Comments on request for renewal: 
 
 
Signature of IREC Chair: 
 
 
Date approved: 
 
 
 
 
 
